Drug Patents Expiring in 2028
1. Abilify Mycite Kit patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9119554 | OTSUKA | Pharma-informatics system |
Dec, 2028
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-150) | Dec 05, 2017 |
| New Indication(I-746) | Jul 27, 2020 |
Drugs and Companies using ARIPIPRAZOLE ingredient
Market Authorisation Date: 13 November, 2017
Treatment: NA
Dosage: TABLET
More Information on Dosage
ABILIFY MYCITE KIT family patents
2. Acuvail patent expiration
ACUVAIL's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9192571 | ABBVIE | Ketorolac tromethamine compositions for treating or preventing ocular pain |
Mar, 2028
(3 years from now) | |
| US8512717 | ABBVIE | Compositions for delivery of therapeutics into the eyes and methods for making and using same |
Mar, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jul 22, 2012 |
Drugs and Companies using KETOROLAC TROMETHAMINE ingredient
Market Authorisation Date: 22 July, 2009
Treatment: NA
Dosage: SOLUTION/DROPS
How can I launch a generic of ACUVAIL before it's drug patent expiration?
More Information on Dosage
ACUVAIL family patents
3. Acuvue Theravision With Ketotifen patent
expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9474746 | JOHNSON JOHNSON VISN | Methods for stabilizing oxidatively unstable compositions |
Mar, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Feb 25, 2025 |
Drugs and Companies using KETOTIFEN FUMARATE ingredient
Market Authorisation Date: 25 February, 2022
Treatment: NA
Dosage: DRUG-ELUTING CONTACT LENS
More Information on Dosage
ACUVUE THERAVISION WITH KETOTIFEN family patents
4. Addyi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7151103 | SPROUT PHARMS | Method of treating female hypoactive sexual desire disorder with flibanserin |
May, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 18, 2020 |
Drugs and Companies using FLIBANSERIN ingredient
NCE-1 date: 19 August, 2019
Market Authorisation Date: 18 August, 2015
Treatment: Use of flibanserin or a pharmaceutically acceptable acid addition salt thereof to treat hypoactive sexual desire disorder (hsdd)
Dosage: TABLET
More Information on Dosage
ADDYI family patents
5. Afinitor patent expiration
AFINITOR's oppositions filed in EPO
AFINITOR IPR and PTAB Proceedings
Can you believe AFINITOR received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9006224 | NOVARTIS | Neuroendocrine tumor treatment |
Jul, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-630) | Oct 29, 2013 |
| New Chemical Entity Exclusivity(NCE) | Mar 30, 2014 |
| New Indication(I-638) | May 05, 2014 |
| New Indication(I-650) | Apr 26, 2015 |
| New Indication(I-655) | Jul 20, 2015 |
| Pediatric Exclusivity(PED) | Apr 29, 2018 |
| Orphan Drug Exclusivity(ODE) | Apr 26, 2019 |
| Orphan Drug Exclusivity(ODE-11) | May 05, 2018 |
| New Indication(I-724) | Feb 26, 2019 |
| Orphan Drug Exclusivity(ODE-24) | Apr 26, 2019 |
| Orphan Drug Exclusivity(ODE-108) | Feb 26, 2023 |
Drugs and Companies using EVEROLIMUS ingredient
NCE-1 date: 26 October, 2014
Market Authorisation Date: 09 July, 2010
Treatment: Treatment of patients with progressive neuroendocrine tumors of pancreatic origin (pnet) that are unresectable, locally advanced or metastatic
Dosage: TABLET
How can I launch a generic of AFINITOR before it's drug patent expiration?
More Information on Dosage
AFINITOR family patents
6. Afrezza patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8729019 | MANNKIND | Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents |
Dec, 2028
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jun 27, 2017 |
Drugs and Companies using INSULIN RECOMBINANT HUMAN ingredient
Market Authorisation Date: 27 June, 2014
Treatment: NA
Dosage: POWDER
More Information on Dosage
AFREZZA family patents
7. Airduo Digihaler patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8651103 | TEVA PHARM | Dry powder inhalation apparatus |
Mar, 2028
(3 years from now) | |
|
US8651103 (Pediatric) | TEVA PHARM | Dry powder inhalation apparatus |
Sep, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-61) | Jul 09, 2024 |
| Pediatric Exclusivity(PED) | Jan 09, 2025 |
Drugs and Companies using FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE ingredient
Market Authorisation Date: 12 July, 2019
Treatment: NA
Dosage: POWDER
More Information on Dosage
AIRDUO DIGIHALER family patents
8. Airduo Respiclick patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8651103 | TEVA PHARM | Dry powder inhalation apparatus |
Mar, 2028
(3 years from now) | |
|
US8651103 (Pediatric) | TEVA PHARM | Dry powder inhalation apparatus |
Sep, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jan 27, 2020 |
| M(M-61) | Jul 09, 2024 |
| Pediatric Exclusivity(PED) | Jan 09, 2025 |
Drugs and Companies using FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE ingredient
Market Authorisation Date: 12 July, 2019
Treatment: NA
Dosage: POWDER
More Information on Dosage
AIRDUO RESPICLICK family patents
9. Alvesco patent expiration
ALVESCO's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8371292 | COVIS | Use of ciclesonide for the treatment of respiratory diseases |
Feb, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 20, 2011 |
| M(M-125) | Dec 17, 2015 |
Drugs and Companies using CICLESONIDE ingredient
NCE-1 date: 20 October, 2010
Market Authorisation Date: 10 January, 2008
Treatment: Maintenance treatment of asthma as prophylactic therapy in adult and adolescent patients 12 years of age and older. patent claims method for treating a respiratory disease in a child
Dosage: AEROSOL, METERED
More Information on Dosage
ALVESCO family patents
10. Ameluz patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11540981 | BIOFRONTERA | Nanoemulsion formulation with improved stability and cell penetration |
Feb, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 10, 2019 |
Drugs and Companies using AMINOLEVULINIC ACID HYDROCHLORIDE ingredient
Market Authorisation Date: 10 May, 2016
Treatment: NA
Dosage: GEL
More Information on Dosage
AMELUZ family patents
11. Amvuttra patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10131907 | ALNYLAM PHARMS INC | Glycoconjugates of RNA interference agents |
Aug, 2028
(3 years from now) | |
| US9370581 | ALNYLAM PHARMS INC | Carbohydrate conjugates as delivery agents for oligonucleotides |
Dec, 2028
(4 years from now) | |
| US8828956 | ALNYLAM PHARMS INC | Carbohydrate conjugates as delivery agents for oligonucleotides |
Dec, 2028
(4 years from now) | |
| US10806791 | ALNYLAM PHARMS INC | Carbohydrate conjugates as delivery agents for oligonucleotides |
Dec, 2028
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 13, 2027 |
| Orphan Drug Exclusivity(ODE-212) | Jun 13, 2029 |
Drugs and Companies using VUTRISIRAN SODIUM ingredient
NCE-1 date: 13 June, 2026
Market Authorisation Date: 13 June, 2022
Treatment: Amvuttra is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults
Dosage: SOLUTION
More Information on Dosage
AMVUTTRA family patents
12. Angiomax patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7582727 | SANDOZ | Pharmaceutical formulations of bivalirudin and processes of making the same |
Jul, 2028
(3 years from now) | |
| US7598343 | SANDOZ | Pharmaceutical formulations of bivalirudin and processes of making the same |
Jul, 2028
(3 years from now) | |
Drugs and Companies using BIVALIRUDIN ingredient
Market Authorisation Date: 15 December, 2000
Treatment: NA
Dosage: INJECTABLE
How can I launch a generic of ANGIOMAX before it's drug patent expiration?
More Information on Dosage
ANGIOMAX family patents
13. Anoro Ellipta patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8161968 | GLAXOSMITHKLINE | Medicament dispenser |
Feb, 2028
(3 years from now) | |
|
US9333310 (Pediatric) | GLAXOSMITHKLINE | Medicament dispenser |
Apr, 2028
(3 years from now) | |
|
US8113199 (Pediatric) | GLAXOSMITHKLINE | Counter for use with a medicament dispenser |
Apr, 2028
(3 years from now) | |
|
US8161968 (Pediatric) | GLAXOSMITHKLINE | Medicament dispenser |
Aug, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Dec 18, 2016 |
| New Chemical Entity Exclusivity(NCE) | Dec 18, 2018 |
| M(M-245) | Jun 09, 2022 |
Drugs and Companies using UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE ingredient
NCE-1 date: 18 December, 2017
Market Authorisation Date: 18 December, 2013
Treatment: NA
Dosage: POWDER
More Information on Dosage
ANORO ELLIPTA family patents
14. Aptiom patent expiration
APTIOM's oppositions filed in EPO
Can you believe APTIOM received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9763954 | SUMITOMO PHARMA AM | Therapeutical uses of eslicarbazepine |
Sep, 2028
(3 years from now) | |
| US10912781 | SUMITOMO PHARMA AM | Pharmaceutical composition comprising licarbazepine acetate |
Oct, 2028
(3 years from now) | |
| US9566244 | SUMITOMO PHARMA AM | Pharmaceutical composition comprising licarbazepine acetate |
Oct, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosing Schedule(D-150) | Aug 27, 2018 |
| New Indication(I-715) | Aug 27, 2018 |
| New Chemical Entity Exclusivity(NCE) | Nov 08, 2018 |
Drugs and Companies using ESLICARBAZEPINE ACETATE ingredient
NCE-1 date: 08 November, 2017
Market Authorisation Date: 08 November, 2013
Treatment: Treatment of partial-onset seizures in patients with epilepsy who have been previously treated with oxcarbazepine
Dosage: TABLET
How can I launch a generic of APTIOM before it's drug patent expiration?
More Information on Dosage
APTIOM family patents
15. Arcapta Neohaler patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8479730 | NOVARTIS | Inhaler device |
Oct, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 01, 2016 |
Drugs and Companies using INDACATEROL MALEATE ingredient
NCE-1 date: 02 July, 2015
Market Authorisation Date: 01 July, 2011
Treatment: NA
Dosage: POWDER
More Information on Dosage
ARCAPTA NEOHALER family patents
16. Arikayce Kit patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8226975 | INSMED INC | Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof |
Aug, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-214) | Sep 28, 2025 |
| Generating Antibiotic Incentives Now(GAIN) | Sep 28, 2030 |
Drugs and Companies using AMIKACIN SULFATE ingredient
Market Authorisation Date: 28 September, 2018
Treatment: NA
Dosage: SUSPENSION, LIPOSOMAL
More Information on Dosage
ARIKAYCE KIT family patents
17. Armonair Digihaler patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8651103 | TEVA PHARM | Dry powder inhalation apparatus |
Mar, 2028
(3 years from now) | |
|
US8651103 (Pediatric) | TEVA PHARM | Dry powder inhalation apparatus |
Sep, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Jul 09, 2024 |
| Pediatric Exclusivity(PED) | Jan 09, 2025 |
Drugs and Companies using FLUTICASONE PROPIONATE ingredient
Market Authorisation Date: 08 April, 2022
Treatment: NA
Dosage: POWDER
More Information on Dosage
ARMONAIR DIGIHALER family patents
18. Armonair Respiclick patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8651103 | TEVA PHARM | Dry powder inhalation apparatus |
Mar, 2028
(3 years from now) | |
|
US8651103 (Pediatric) | TEVA PHARM | Dry powder inhalation apparatus |
Sep, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jan 27, 2020 |
| New Patient Population(NPP) | Jul 09, 2024 |
| New Strength(NS) | Jul 09, 2024 |
| Pediatric Exclusivity(PED) | Jan 09, 2025 |
Drugs and Companies using FLUTICASONE PROPIONATE ingredient
Market Authorisation Date: 08 April, 2022
Treatment: NA
Dosage: POWDER
More Information on Dosage
ARMONAIR RESPICLICK family patents
19. Arnuity Ellipta patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8161968 | GLAXOSMITHKLINE | Medicament dispenser |
Feb, 2028
(3 years from now) | |
|
US9333310 (Pediatric) | GLAXOSMITHKLINE | Medicament dispenser |
Apr, 2028
(3 years from now) | |
|
US8113199 (Pediatric) | GLAXOSMITHKLINE | Counter for use with a medicament dispenser |
Apr, 2028
(3 years from now) | |
|
US8161968 (Pediatric) | GLAXOSMITHKLINE | Medicament dispenser |
Aug, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Aug 20, 2017 |
| New Patient Population(NPP) | May 17, 2021 |
| New Strength(NS) | May 17, 2021 |
| M(M-290) | Mar 01, 2026 |
Drugs and Companies using FLUTICASONE FUROATE ingredient
Market Authorisation Date: 17 May, 2018
Treatment: NA
Dosage: POWDER
More Information on Dosage
ARNUITY ELLIPTA family patents
20. Astepro patent expiration
ASTEPRO IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8071073 | MEDA PHARMS | Compositions comprising azelastine and methods of use thereof |
Jun, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Aug 31, 2012 |
| M(M-129) | Aug 30, 2016 |
| New Patient Population(NPP) | Feb 20, 2018 |
Drugs and Companies using AZELASTINE HYDROCHLORIDE ingredient
Market Authorisation Date: 31 August, 2009
Treatment: NA
Dosage: SPRAY, METERED
How can I launch a generic of ASTEPRO before it's drug patent expiration?
More Information on Dosage
ASTEPRO family patents
21. Astepro patent expiration
ASTEPRO IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8071073 | MYLAN SPECIALITY LP | Compositions comprising azelastine and methods of use thereof |
Jun, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Aug 31, 2012 |
| M(M-129) | Aug 30, 2016 |
| New Patient Population(NPP) | Feb 20, 2018 |
Drugs and Companies using AZELASTINE HYDROCHLORIDE ingredient
Market Authorisation Date: 15 October, 2008
Treatment: NA
Dosage: SPRAY, METERED
How can I launch a generic of ASTEPRO before it's drug patent expiration?
More Information on Dosage
ASTEPRO family patents
22. Astepro Allergy patent expiration
ASTEPRO ALLERGY IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8071073 | BAYER HLTHCARE | Compositions comprising azelastine and methods of use thereof |
Jun, 2028
(3 years from now) | |
Drugs and Companies using AZELASTINE HYDROCHLORIDE ingredient
Market Authorisation Date: 17 June, 2021
Treatment: NA
Dosage: SPRAY, METERED
How can I launch a generic of ASTEPRO ALLERGY before it's drug patent expiration?
More Information on Dosage
ASTEPRO ALLERGY family patents
23. Atelvia patent expiration
ATELVIA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7645459 | APIL | Dosage forms of bisphosphonates |
Jan, 2028
(3 years from now) | |
| US7645460 | APIL | Dosage forms of risedronate |
Jan, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Oct 08, 2013 |
Drugs and Companies using RISEDRONATE SODIUM ingredient
Market Authorisation Date: 08 October, 2010
Treatment: Treatment of osteoporosis in postmenopausal women
Dosage: TABLET, DELAYED RELEASE
How can I launch a generic of ATELVIA before it's drug patent expiration?
More Information on Dosage
ATELVIA family patents
24. Auvi-q patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7947017 | KALEO INC | Devices, systems and methods for medicament delivery |
Mar, 2028
(3 years from now) | |
| US7749194 | KALEO INC | Devices, systems, and methods for medicament delivery |
Oct, 2028
(3 years from now) | |
| US8231573 | KALEO INC | Medicament delivery device having an electronic circuit system |
Nov, 2028
(4 years from now) | |
Drugs and Companies using EPINEPHRINE ingredient
Market Authorisation Date: 17 November, 2017
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
AUVI-Q family patents
25. Bevyxxa patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8557852 | PORTOLA PHARMS INC | Methods of using crystalline forms of a salt of a factor Xa inhibitor |
Sep, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 23, 2022 |
Drugs and Companies using BETRIXABAN ingredient
NCE-1 date: 23 June, 2021
Market Authorisation Date: 23 June, 2017
Treatment: Prophylaxis of venous thrombosis
Dosage: CAPSULE
More Information on Dosage
BEVYXXA family patents
26. Brenzavvy patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8802637 | THERACOSBIO | Benzylbenzene derivatives and methods of use |
Aug, 2028
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8106021 | THERACOSBIO | Benzylbenzene derivatives and methods of use |
Aug, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 20, 2028 |
Drugs and Companies using BEXAGLIFLOZIN ingredient
NCE-1 date: 20 January, 2027
Market Authorisation Date: 20 January, 2023
Treatment: An adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes
Dosage: TABLET
More Information on Dosage
BRENZAVVY family patents
27. Breo Ellipta patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8161968 | GLAXO GRP LTD | Medicament dispenser |
Feb, 2028
(3 years from now) | |
|
US9333310 (Pediatric) | GLAXO GRP LTD | Medicament dispenser |
Apr, 2028
(3 years from now) | |
|
US8113199 (Pediatric) | GLAXO GRP LTD | Counter for use with a medicament dispenser |
Apr, 2028
(3 years from now) | |
|
US8161968 (Pediatric) | GLAXO GRP LTD | Medicament dispenser |
Aug, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Apr 30, 2018 |
| New Indication(I-708) | Apr 30, 2018 |
| New Chemical Entity Exclusivity(NCE) | May 10, 2018 |
| M(M-202) | May 15, 2020 |
| New Patient Population(NPP) | May 13, 2026 |
| New Strength(NS) | May 13, 2026 |
| Pediatric Exclusivity(PED) | Nov 13, 2026 |
Drugs and Companies using FLUTICASONE FUROATE; VILANTEROL TRIFENATATE ingredient
NCE-1 date: 13 November, 2025
Market Authorisation Date: 12 May, 2023
Treatment: NA
Dosage: POWDER
More Information on Dosage
BREO ELLIPTA family patents
28. Bydureon patent expiration
BYDUREON's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8216180 | ASTRAZENECA AB | Administering apparatus with functional drive element |
Jan, 2028
(3 years from now) | |
| US8361972 | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Mar, 2028
(3 years from now) | |
| US8221786 | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Mar, 2028
(3 years from now) | |
| US8716251 | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Mar, 2028
(3 years from now) | |
| US8439864 | ASTRAZENECA AB | Device for administering fluid from a multi-chamber ampoule in incremental steps |
Mar, 2028
(3 years from now) | |
| US7851502 | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Aug, 2028
(3 years from now) | |
|
US8361972 (Pediatric) | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Sep, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jan 27, 2015 |
| M(M-162) | Sep 24, 2018 |
| M(M-212) | Oct 20, 2020 |
| M(M-224) | Apr 02, 2021 |
| M(M-240) | Feb 15, 2022 |
| New Patient Population(NPP) | Jul 22, 2024 |
| Pediatric Exclusivity(PED) | Jan 22, 2025 |
Drugs and Companies using EXENATIDE SYNTHETIC ingredient
Market Authorisation Date: 27 January, 2012
Treatment: As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin and metformin
Dosage: FOR SUSPENSION, EXTENDED RELEASE
More Information on Dosage
BYDUREON family patents
29. Bydureon Bcise patent expiration
BYDUREON BCISE's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8361972 | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Mar, 2028
(3 years from now) | |
|
US8361972 (Pediatric) | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Sep, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 20, 2020 |
| M(M-240) | Feb 15, 2022 |
| New Patient Population(NPP) | Jul 22, 2024 |
| Pediatric Exclusivity(PED) | Jan 22, 2025 |
Drugs and Companies using EXENATIDE SYNTHETIC ingredient
Market Authorisation Date: 20 October, 2017
Treatment: As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin and metformin
Dosage: SUSPENSION, EXTENDED RELEASE
More Information on Dosage
BYDUREON BCISE family patents
30. Bydureon Pen patent expiration
BYDUREON PEN's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8216180 | ASTRAZENECA AB | Administering apparatus with functional drive element |
Jan, 2028
(3 years from now) | |
| US8221786 | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Mar, 2028
(3 years from now) | |
| US8361972 | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Mar, 2028
(3 years from now) | |
| US8716251 | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Mar, 2028
(3 years from now) | |
| US8439864 | ASTRAZENECA AB | Device for administering fluid from a multi-chamber ampoule in incremental steps |
Mar, 2028
(3 years from now) | |
| US9320853 | ASTRAZENECA AB | Method for administering a fluid active substance from a multi-chamber ampoule |
Mar, 2028
(3 years from now) | |
|
US8758292 (Pediatric) | ASTRAZENECA AB | Administering apparatus with functional drive element |
May, 2028
(3 years from now) | |
|
US8216180 (Pediatric) | ASTRAZENECA AB | Administering apparatus with functional drive element |
Jul, 2028
(3 years from now) | |
| US7851502 | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Aug, 2028
(3 years from now) | |
|
US8361972 (Pediatric) | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Sep, 2028
(3 years from now) | |
|
US9320853 (Pediatric) | ASTRAZENECA AB | Method for administering a fluid active substance from a multi-chamber ampoule |
Sep, 2028
(3 years from now) | |
|
US8439864 (Pediatric) | ASTRAZENECA AB | Device for administering fluid from a multi-chamber ampoule in incremental steps |
Sep, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-224) | Apr 02, 2021 |
| M(M-240) | Feb 15, 2022 |
| New Patient Population(NPP) | Jul 22, 2024 |
| Pediatric Exclusivity(PED) | Jan 22, 2025 |
Drugs and Companies using EXENATIDE SYNTHETIC ingredient
Market Authorisation Date: 27 January, 2012
Treatment: As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin and metformin
Dosage: FOR SUSPENSION, EXTENDED RELEASE
More Information on Dosage
BYDUREON PEN family patents
31. Canasa patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8436051 | ABBVIE | Mesalamine suppository |
Jun, 2028
(3 years from now) | |
| US8217083 | ABBVIE | Mesalamine suppository |
Jun, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-187) | Sep 02, 2019 |
Drugs and Companies using MESALAMINE ingredient
Market Authorisation Date: 05 November, 2004
Treatment: NA
Dosage: SUPPOSITORY
How can I launch a generic of CANASA before it's drug patent expiration?
More Information on Dosage
CANASA family patents
32. Caplyta patent expiration
Can you believe CAPLYTA received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10464938 | INTRA-CELLULAR | Pharmaceutical compositions comprising ((6bR,10aS)-1-(4-fluorophenyl)-4-(3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)butan-1-one or pharmaceutically acceptable salts thereof |
Mar, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-882) | Dec 17, 2024 |
| New Chemical Entity Exclusivity(NCE) | Dec 20, 2024 |
Drugs and Companies using LUMATEPERONE TOSYLATE ingredient
NCE-1 date: 21 December, 2023
Market Authorisation Date: 22 April, 2022
Treatment: NA
Dosage: CAPSULE
More Information on Dosage
CAPLYTA family patents
33. Caprelsa patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8067427 | GENZYME CORP | Pharmaceutical compositions comprising ZD6474 |
Aug, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 06, 2016 |
| Orphan Drug Exclusivity(ODE) | Apr 06, 2018 |
| Orphan Drug Exclusivity(ODE-9) | Apr 06, 2018 |
Drugs and Companies using VANDETANIB ingredient
NCE-1 date: 07 April, 2015
Market Authorisation Date: 06 April, 2011
Treatment: NA
Dosage: TABLET
More Information on Dosage
CAPRELSA family patents
34. Carnexiv patent expiration
CARNEXIV's oppositions filed in EPO
CARNEXIV IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9629797 | LUNDBECK PHARMS LLC | Parenteral carbamazepine formulation |
Nov, 2028
(4 years from now) | |
| US9770407 | LUNDBECK PHARMS LLC | Parenteral carbamazepine formulation |
Nov, 2028
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | Oct 07, 2023 |
| Orphan Drug Exclusivity(ODE-124) | Oct 07, 2023 |
Drugs and Companies using CARBAMAZEPINE ingredient
Market Authorisation Date: 07 October, 2016
Treatment: Replacement therapy for oral carbamazepine in adults with mixed seizure patterns that include partial seizures with complex symptomatology, generalized tonic-clonic seizures, or other partial or gener...
Dosage: SOLUTION
More Information on Dosage
CARNEXIV family patents
35. Children's Astepro Allergy patent expiration
CHILDREN'S ASTEPRO ALLERGY IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8071073 | BAYER HLTHCARE | Compositions comprising azelastine and methods of use thereof |
Jun, 2028
(3 years from now) | |
Drugs and Companies using AZELASTINE HYDROCHLORIDE ingredient
Market Authorisation Date: 17 June, 2021
Treatment: NA
Dosage: SPRAY, METERED
How can I launch a generic of CHILDREN'S ASTEPRO ALLERGY before it's drug patent expiration?
More Information on Dosage
CHILDREN'S ASTEPRO ALLERGY family patents
36. Colcrys patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8415395 | TAKEDA PHARMS USA | Colchicine compositions and methods |
Oct, 2028
(3 years from now) | |
| US8093298 | TAKEDA PHARMS USA | Methods for concomitant administration of colchicine and macrolide antibiotics |
Oct, 2028
(3 years from now) | |
| US7981938 | TAKEDA PHARMS USA | Colchicine compositions and methods |
Oct, 2028
(3 years from now) | |
| US8093296 | TAKEDA PHARMS USA | Methods for concomitant administration of colchicine and macrolide antibiotics |
Oct, 2028
(3 years from now) | |
| US8415396 | TAKEDA PHARMS USA | Colchine compositions and methods |
Oct, 2028
(3 years from now) | |
| US7964648 | TAKEDA PHARMS USA | Methods for concomitant administration of colchicine and a second active agent |
Oct, 2028
(3 years from now) | |
| US8097655 | TAKEDA PHARMS USA | Methods for concomitant administration of colchicine and macrolide antibiotics |
Oct, 2028
(3 years from now) | |
| US8093297 | TAKEDA PHARMS USA | Methods for concomitant administration of colchicine and a second active agent |
Oct, 2028
(3 years from now) | |
| US7964647 | TAKEDA PHARMS USA | Colchicine compositions and methods |
Oct, 2028
(3 years from now) | |
| US7619004 | TAKEDA PHARMS USA | Methods for concomitant administration of colchicine and macrolide antibiotics |
Dec, 2028
(4 years from now) | |
| US7935731 | TAKEDA PHARMS USA | Methods for concomitant administration of colchicine and macrolide antibiotics |
Dec, 2028
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-603) | Jul 30, 2012 |
| Orphan Drug Exclusivity(ODE) | Jul 29, 2016 |
Drugs and Companies using COLCHICINE ingredient
Market Authorisation Date: 29 July, 2009
Treatment: Method of treating gout flares; Method of administering colchicine to familial mediterranean fever patients; A method for treatment of gout flares during prophylaxis; For the treatment and prophylaxis...
Dosage: TABLET
How can I launch a generic of COLCRYS before it's drug patent expiration?
More Information on Dosage
COLCRYS family patents
37. Combivent Respimat patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7837235 | BOEHRINGER INGELHEIM | Device for clamping a fluidic component |
Mar, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 07, 2014 |
Drugs and Companies using ALBUTEROL SULFATE; IPRATROPIUM BROMIDE ingredient
Market Authorisation Date: 07 October, 2011
Treatment: NA
Dosage: SPRAY, METERED
How can I launch a generic of COMBIVENT RESPIMAT before it's drug patent expiration?
More Information on Dosage
COMBIVENT RESPIMAT family patents
38. Cresemba patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US10206879 (Pediatric) | ASTELLAS | Active ingredient containing stabilised solid forms and method for the production thereof |
Mar, 2028
(3 years from now) | |
|
US10603280 (Pediatric) | ASTELLAS | Active ingredient containing stabilised solid medicinal forms and methods for the production thereof |
Mar, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 06, 2020 |
| Orphan Drug Exclusivity(ODE) | Mar 06, 2022 |
| ODE*(ODE*) | Mar 06, 2022 |
| Orphan Drug Exclusivity(ODE-305) | Mar 06, 2022 |
| Orphan Drug Exclusivity(ODE-90) | Mar 06, 2022 |
| New Patient Population(NPP) | Dec 08, 2026 |
| Generating Antibiotic Incentives Now(GAIN) | Sep 06, 2027 |
| Orphan Drug Exclusivity(ODE-453) | Dec 08, 2030 |
| Orphan Drug Exclusivity(ODE-454) | Dec 08, 2030 |
| Orphan Drug Exclusivity(ODE-458) | Dec 08, 2030 |
| Orphan Drug Exclusivity(ODE-459) | Dec 08, 2030 |
| Pediatric Exclusivity(PED) | Jun 08, 2031 |
Drugs and Companies using ISAVUCONAZONIUM SULFATE ingredient
NCE-1 date: 08 June, 2030
Market Authorisation Date: 22 November, 2022
Treatment: NA
Dosage: CAPSULE
More Information on Dosage
CRESEMBA family patents
39. Cubicin patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8003673 | CUBIST PHARMS LLC | Daptomycin for the treatment of biofilm and catheter salvage |
Sep, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Mar 29, 2020 |
| M(M-211) | Sep 01, 2020 |
Drugs and Companies using DAPTOMYCIN ingredient
Market Authorisation Date: 12 September, 2003
Treatment: Treatment of the following infections: complicated skin and skin structure infections and staphylococcus aureus bloodstream infections (bacteremia) including those with right-sided infective endocardi...
Dosage: POWDER
How can I launch a generic of CUBICIN before it's drug patent expiration?
More Information on Dosage
CUBICIN family patents
40. Dalvance patent expiration
DALVANCE's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6900175 | ABBVIE | Methods of administering dalbavancin for treatment of bacterial infections |
May, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosing Schedule(D-154) | Jan 20, 2019 |
| New Chemical Entity Exclusivity(NCE) | May 23, 2019 |
| Generating Antibiotic Incentives Now(GAIN) | May 23, 2024 |
| New Patient Population(NPP) | Jul 22, 2024 |
Drugs and Companies using DALBAVANCIN HYDROCHLORIDE ingredient
NCE-1 date: 24 May, 2023
Market Authorisation Date: 23 May, 2014
Treatment: Treatment of acute bacterial skin and skin structure infections (absssi) in adult and pediatric patients using a two-dose regimen of dalbavancin
Dosage: POWDER
More Information on Dosage
DALVANCE family patents
41. Daurismo patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8431597 | PFIZER | Benzimidazole derivatives |
Jun, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 21, 2023 |
| Orphan Drug Exclusivity(ODE-224) | Nov 21, 2025 |
Drugs and Companies using GLASDEGIB MALEATE ingredient
NCE-1 date: 21 November, 2022
Market Authorisation Date: 21 November, 2018
Treatment: NA
Dosage: TABLET
More Information on Dosage
DAURISMO family patents
42. Dexilant patent expiration
DEXILANT's oppositions filed in EPO
Can you believe DEXILANT received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8871273 | TAKEDA PHARMS USA | Method for producing granules |
Jan, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jan 30, 2012 |
| Pediatric Exclusivity(PED) | Jul 30, 2012 |
| New Patient Population(NPP) | Jul 08, 2019 |
Drugs and Companies using DEXLANSOPRAZOLE ingredient
Market Authorisation Date: 30 January, 2009
Treatment: NA
Dosage: CAPSULE, DELAYED RELEASE
How can I launch a generic of DEXILANT before it's drug patent expiration?
More Information on Dosage
DEXILANT family patents
43. Dexilant Solutab patent expiration
DEXILANT SOLUTAB's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8871273 | TAKEDA PHARMS USA | Method for producing granules |
Jan, 2028
(3 years from now) | |
|
US8871273 (Pediatric) | TAKEDA PHARMS USA | Method for producing granules |
Jul, 2028
(3 years from now) | |
Drugs and Companies using DEXLANSOPRAZOLE ingredient
Market Authorisation Date: 26 January, 2016
Treatment: NA
Dosage: TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE
More Information on Dosage
DEXILANT SOLUTAB family patents
44. Differin patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7998467 | GALDERMA LABS LP | Cosmetic/dermatological compositions comprising naphthoic acid compounds and polyurethane polymers |
May, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Mar 17, 2013 |
| RTO(RTO) | Jul 08, 2019 |
Drugs and Companies using ADAPALENE ingredient
Market Authorisation Date: 17 March, 2010
Treatment: Treatment of acne
Dosage: LOTION
How can I launch a generic of DIFFERIN before it's drug patent expiration?
More Information on Dosage
DIFFERIN family patents
45. Dificid patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7378508 (Pediatric) | CUBIST PHARMS LLC | Polymorphic crystalline forms of tiacumicin B |
Jan, 2028
(3 years from now) | |
|
US7863249 (Pediatric) | CUBIST PHARMS LLC | Macrolide polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof |
Jan, 2028
(3 years from now) | |
|
US8859510 (Pediatric) | CUBIST PHARMS LLC | Macrocyclic polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof |
Jan, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 27, 2016 |
| New Product(NP) | Jan 24, 2023 |
| New Patient Population(NPP) | Jan 24, 2023 |
| Pediatric Exclusivity(PED) | Jul 24, 2023 |
| Orphan Drug Exclusivity(ODE-367) | Jan 24, 2027 |
Drugs and Companies using FIDAXOMICIN ingredient
Market Authorisation Date: 24 January, 2020
Treatment: NA
Dosage: FOR SUSPENSION; TABLET
How can I launch a generic of DIFICID before it's drug patent expiration?
More Information on Dosage
DIFICID family patents
46. Doral patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7608616 | GALT PHARMS | Methods for reducing the risk of an adverse drug interaction in a patient suffering from insomnia |
Jun, 2028
(3 years from now) | |
Drugs and Companies using QUAZEPAM ingredient
Market Authorisation Date: 26 February, 1987
Treatment: Method for treating insomnia while reducing the risk of an adverse drug interaction
Dosage: TABLET
More Information on Dosage
DORAL family patents
47. Doryx patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8715724 | MAYNE PHARMA | Tabletting process |
Feb, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosing Schedule(D-136) | Apr 11, 2016 |
| New Strength(NS) | Apr 11, 2016 |
Drugs and Companies using DOXYCYCLINE HYCLATE ingredient
Market Authorisation Date: 19 December, 2014
Treatment: NA
Dosage: TABLET, DELAYED RELEASE
How can I launch a generic of DORYX before it's drug patent expiration?
More Information on Dosage
DORYX family patents
48. Doryx Mpc patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8715724 | MAYNE PHARMA | Tabletting process |
Feb, 2028
(3 years from now) | |
Drugs and Companies using DOXYCYCLINE HYCLATE ingredient
Market Authorisation Date: 19 December, 2014
Treatment: NA
Dosage: TABLET, DELAYED RELEASE
How can I launch a generic of DORYX MPC before it's drug patent expiration?
More Information on Dosage
DORYX MPC family patents
49. Dovato patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8129385 (Pediatric) | VIIV HLTHCARE | Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness |
Apr, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Apr 08, 2022 |
| New Indication(I-839) | Aug 06, 2023 |
| New Patient Population(NPP) | Apr 05, 2027 |
Drugs and Companies using DOLUTEGRAVIR SODIUM; LAMIVUDINE ingredient
Market Authorisation Date: 08 April, 2019
Treatment: NA
Dosage: TABLET
How can I launch a generic of DOVATO before it's drug patent expiration?
More Information on Dosage
DOVATO family patents
50. Duetact patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8071130 | TAKEDA PHARMS USA | Solid preparation |
Jun, 2028
(3 years from now) | |
Drugs and Companies using GLIMEPIRIDE; PIOGLITAZONE HYDROCHLORIDE ingredient
Market Authorisation Date: 28 July, 2006
Treatment: NA
Dosage: TABLET
How can I launch a generic of DUETACT before it's drug patent expiration?
More Information on Dosage
DUETACT family patents
51. Duzallo patent expiration
Can you believe DUZALLO received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10183012 | IRONWOOD PHARMS INC | Compounds and compositions and methods of use |
Nov, 2028
(4 years from now) | |
| US8283369 | IRONWOOD PHARMS INC | Compounds and compositions and methods of use |
Nov, 2028
(4 years from now) | |
Drugs and Companies using ALLOPURINOL; LESINURAD ingredient
Market Authorisation Date: 18 August, 2017
Treatment: Treatment of hyperuricemia associated with gout in patients who have not achieved target serum uric acid levels with a medically appropriate daily dose of allopurinol alone
Dosage: TABLET
More Information on Dosage
DUZALLO family patents
52. Edarbi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9066936 | AZURITY | Solid pharmaceutical composition comprising a benzimidazole-7-carboxylate derivative and a pH control agent |
Mar, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 25, 2016 |
Drugs and Companies using AZILSARTAN KAMEDOXOMIL ingredient
NCE-1 date: 25 February, 2015
Market Authorisation Date: 25 February, 2011
Treatment: NA
Dosage: TABLET
How can I launch a generic of EDARBI before it's drug patent expiration?
More Information on Dosage
EDARBI family patents
53. Edarbyclor patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9066936 | AZURITY | Solid pharmaceutical composition comprising a benzimidazole-7-carboxylate derivative and a pH control agent |
Mar, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Dec 20, 2014 |
| New Chemical Entity Exclusivity(NCE) | Feb 25, 2016 |
Drugs and Companies using AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE ingredient
NCE-1 date: 25 February, 2015
Market Authorisation Date: 20 December, 2011
Treatment: NA
Dosage: TABLET
How can I launch a generic of EDARBYCLOR before it's drug patent expiration?
More Information on Dosage
EDARBYCLOR family patents
54. Ella patent expiration
ELLA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9844510 | LAB HRA PHARMA | Ulipristal acetate tablets |
Dec, 2028
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 13, 2015 |
| M(M-271) | Jun 24, 2024 |
Drugs and Companies using ULIPRISTAL ACETATE ingredient
NCE-1 date: 13 August, 2014
Market Authorisation Date: 13 August, 2010
Treatment: NA
Dosage: TABLET
How can I launch a generic of ELLA before it's drug patent expiration?
More Information on Dosage
ELLA family patents
55. Elucirem patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8114863 | GUERBET | Compounds comprising short aminoalcohol chains and metal complexes for medical imaging |
Sep, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 21, 2027 |
Drugs and Companies using GADOPICLENOL ingredient
NCE-1 date: 21 September, 2026
Market Authorisation Date: 21 September, 2022
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
ELUCIREM family patents
56. Envarsus Xr patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11419823 | VELOXIS PHARMS INC | Stabilized tacrolimus composition |
May, 2028
(3 years from now) | |
| US10166190 | VELOXIS PHARMS INC | Stabilized tacrolimus composition |
May, 2028
(3 years from now) | |
| US9549918 | VELOXIS PHARMS INC | Stabilized tacrolimus composition |
May, 2028
(3 years from now) | |
| US11123331 | VELOXIS PHARMS INC | Tacrolimus for improved treatment of transplant patients |
May, 2028
(3 years from now) | |
| US12083103 | VELOXIS PHARMS INC | Tacrolimus for improved treatment of transplant patients |
May, 2028
(3 years from now) | |
| US10864199 | VELOXIS PHARMS INC | Tacrolimus for improved treatment of transplant patients |
May, 2028
(3 years from now) | |
| US11110081 | VELOXIS PHARMS INC | Tacrolimus for improved treatment of transplant patients |
May, 2028
(3 years from now) | |
| US8644239 | VELOXIS PHARMS INC | Method and apparatus for allocating and processing sequences in communication system |
Aug, 2028
(3 years from now) | |
| US8685998 | VELOXIS PHARMS INC | Tacrolimus for improved treatment of transplant patients |
Aug, 2028
(3 years from now) | |
| US8664239 | VELOXIS PHARMS INC | Tacrolimus for improved treatment of transplant patients |
Aug, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | Jul 10, 2022 |
| Orphan Drug Exclusivity(ODE-94) | Jul 10, 2022 |
Drugs and Companies using TACROLIMUS ingredient
Market Authorisation Date: 10 July, 2015
Treatment: Prophylaxis of organ rejection in patients converted from tacrolimus immediate-release formulations; Prophylaxis of organ rejection in de novo transplant patient
Dosage: TABLET, EXTENDED RELEASE
How can I launch a generic of ENVARSUS XR before it's drug patent expiration?
More Information on Dosage
ENVARSUS XR family patents
57. Eohilia patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11357859 | TAKEDA PHARMS USA | Compositions for the treatment of gastrointestinal inflammation |
Nov, 2028
(4 years from now) | |
| US10293052 | TAKEDA PHARMS USA | Compositions for the treatment of gastrointestinal inflammation |
Nov, 2028
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Feb 09, 2027 |
| Orphan Drug Exclusivity(ODE-466) | Feb 09, 2031 |
Drugs and Companies using BUDESONIDE ingredient
Market Authorisation Date: 09 February, 2024
Treatment: Treatment of eosinophilic esophagitis
Dosage: SUSPENSION
More Information on Dosage
EOHILIA family patents
58. Epclusa patent expiration
EPCLUSA's oppositions filed in EPO
EPCLUSA IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8334270 | GILEAD SCIENCES INC | NA |
Mar, 2028
(3 years from now) | |
| US8580765 | GILEAD SCIENCES INC | NA |
Mar, 2028
(3 years from now) | |
| US9085573 | GILEAD SCIENCES INC | NA |
Mar, 2028
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8735372 | GILEAD SCIENCES INC | NA |
Mar, 2028
(3 years from now) | |
|
US8334270 (Pediatric) | GILEAD SCIENCES INC | NA |
Sep, 2028
(3 years from now) | |
|
US8580765 (Pediatric) | GILEAD SCIENCES INC | NA |
Sep, 2028
(3 years from now) | |
|
US9085573 (Pediatric) | GILEAD SCIENCES INC | NA |
Sep, 2028
(3 years from now) | |
|
US8735372 (Pediatric) | GILEAD SCIENCES INC | NA |
Sep, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 28, 2021 |
| New Dosing Schedule(D-177) | Nov 15, 2022 |
| New Patient Population(NPP) | Mar 19, 2023 |
| New Strength(NS) | Mar 19, 2023 |
| M(M-264) | Jul 14, 2023 |
| M(M-277) | Apr 27, 2025 |
| Orphan Drug Exclusivity(ODE-293) | Mar 19, 2027 |
| Orphan Drug Exclusivity(ODE-376) | Jun 10, 2028 |
| Pediatric Exclusivity(PED) | Dec 10, 2028 |
Drugs and Companies using SOFOSBUVIR; VELPATASVIR ingredient
NCE-1 date: 11 December, 2027
Market Authorisation Date: 19 March, 2020
Treatment: For the treatment of hepatitis c
Dosage: TABLET; PELLETS
More Information on Dosage
EPCLUSA family patents
59. Epsolay patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9868103 | GALDERMA LABS LP | Metal oxide coating of water insoluble ingredients |
Aug, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Apr 22, 2025 |
Drugs and Companies using BENZOYL PEROXIDE ingredient
Market Authorisation Date: 22 April, 2022
Treatment: Topical treatment of inflammatory lesions of rosacea in adults 18 years of age and older
Dosage: CREAM
More Information on Dosage
EPSOLAY family patents
60. Erivedge patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7888364 | GENENTECH | Pyridyl inhibitors of hedgehog signalling |
Nov, 2028
(4 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9278961 | GENENTECH | Pyridyl inhibitors of hedgehog signalling |
Dec, 2028
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 30, 2017 |
Drugs and Companies using VISMODEGIB ingredient
NCE-1 date: 31 January, 2016
Market Authorisation Date: 30 January, 2012
Treatment: Method of using vismodegib to treat cancer in a mammal
Dosage: CAPSULE
More Information on Dosage
ERIVEDGE family patents
61. Esbriet patent expiration
ESBRIET's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8383150 | GENENTECH INC | Granulate formulation of pirfenidone and pharmaceutically acceptable excipients |
May, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 15, 2019 |
| Orphan Drug Exclusivity(ODE) | Oct 15, 2021 |
| Orphan Drug Exclusivity(ODE-77) | Oct 15, 2021 |
Drugs and Companies using PIRFENIDONE ingredient
NCE-1 date: 15 October, 2018
Market Authorisation Date: 11 January, 2017
Treatment: Method of administering a granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone as recited in claim 1, to treat idiopathic pulmonary fibrosis
Dosage: TABLET
How can I launch a generic of ESBRIET before it's drug patent expiration?
More Information on Dosage
ESBRIET family patents
62. Evzio patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7947017 | KALEO INC | Devices, systems and methods for medicament delivery |
Mar, 2028
(3 years from now) | |
| US7749194 | KALEO INC | Devices, systems, and methods for medicament delivery |
Oct, 2028
(3 years from now) | |
| US8231573 | KALEO INC | Medicament delivery device having an electronic circuit system |
Nov, 2028
(4 years from now) | |
Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 03 April, 2014
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
EVZIO family patents
63. Evzio (autoinjector) patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7947017 | KALEO INC | Devices, systems and methods for medicament delivery |
Mar, 2028
(3 years from now) | |
| US7749194 | KALEO INC | Devices, systems, and methods for medicament delivery |
Oct, 2028
(3 years from now) | |
| US8231573 | KALEO INC | Medicament delivery device having an electronic circuit system |
Nov, 2028
(4 years from now) | |
Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 19 October, 2016
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
EVZIO (AUTOINJECTOR) family patents
64. Exondys 51 patent expiration
EXONDYS 51's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9243245 | SAREPTA THERAPS INC | Means and methods for counteracting muscle disorders |
Oct, 2028
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| USRE48468 | SAREPTA THERAPS INC | Means and methods for counteracting muscle disorders |
Oct, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 19, 2021 |
| Orphan Drug Exclusivity(ODE) | Sep 19, 2023 |
| Orphan Drug Exclusivity(ODE-122) | Sep 19, 2023 |
Drugs and Companies using ETEPLIRSEN ingredient
NCE-1 date: 19 September, 2020
Market Authorisation Date: 19 September, 2016
Treatment: Treatment of dmd in patients having a mutation of the dmd gene that is amenable to exon 51 skipping; Increasing production of functional dystrophin protein in dmd patients having a mutation of the dmd...
Dosage: SOLUTION
More Information on Dosage
EXONDYS 51 family patents
65. Farxiga patent expiration
FARXIGA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8221786 | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Mar, 2028
(3 years from now) | |
| US8716251 | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Mar, 2028
(3 years from now) | |
| US8361972 | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Mar, 2028
(3 years from now) | |
| US7851502 | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Aug, 2028
(3 years from now) | |
|
US8716251 (Pediatric) | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Sep, 2028
(3 years from now) | |
|
US8221786 (Pediatric) | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Sep, 2028
(3 years from now) | |
|
US8361972 (Pediatric) | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Sep, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-157) | Mar 11, 2018 |
| New Chemical Entity Exclusivity(NCE) | Jan 08, 2019 |
| M(M-212) | Oct 20, 2020 |
| M(M-238) | Feb 22, 2022 |
| New Indication(I-841) | Oct 18, 2022 |
| New Indication(I-834) | May 05, 2023 |
| New Indication(I-857) | Apr 30, 2024 |
| M(M-298) | May 08, 2026 |
| New Patient Population(NPP) | Jun 12, 2027 |
| Pediatric Exclusivity(PED) | Dec 12, 2027 |
Drugs and Companies using DAPAGLIFLOZIN ingredient
NCE-1 date: 12 December, 2026
Market Authorisation Date: 08 January, 2014
Treatment: Treatment of type 2 diabetes mellitus
Dosage: TABLET
How can I launch a generic of FARXIGA before it's drug patent expiration?
More Information on Dosage
FARXIGA family patents
66. Farydak patent expiration
FARYDAK's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7989494 | SECURA | Polymorphs of N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2E-2-propenamide |
Jan, 2028
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8883842 | SECURA | Use of HDAC inhibitors for the treatment of myeloma |
Jun, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 23, 2020 |
| Orphan Drug Exclusivity(ODE) | Feb 23, 2022 |
| Orphan Drug Exclusivity(ODE-89) | Feb 23, 2022 |
Drugs and Companies using PANOBINOSTAT LACTATE ingredient
NCE-1 date: 23 February, 2019
Market Authorisation Date: 23 February, 2015
Treatment: Treatment of multiple myeloma, in combination with bortezomib and dexamethasone
Dosage: CAPSULE
More Information on Dosage
FARYDAK family patents
67. Fentora patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7862832 | CEPHALON | Generally linear effervescent oral fentanyl dosage form and methods of administering |
Jun, 2028
(3 years from now) | |
| US7862833 | CEPHALON | Effervescent oral opiate dosage forms and methods of administering opiates |
Jun, 2028
(3 years from now) | |
Drugs and Companies using FENTANYL CITRATE ingredient
Market Authorisation Date: 25 September, 2006
Treatment: NA
Dosage: TABLET
How can I launch a generic of FENTORA before it's drug patent expiration?
More Information on Dosage
FENTORA family patents
68. Flo-pred patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7799331 | TARO | Oral suspension of prednisolone acetate |
Oct, 2028
(3 years from now) | |
Drugs and Companies using PREDNISOLONE ACETATE ingredient
Market Authorisation Date: 17 January, 2008
Treatment: Treatment of asthma
Dosage: SUSPENSION
More Information on Dosage
FLO-PRED family patents
69. Flonase Sensimist Allergy Relief patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8347879 | HALEON US HOLDINGS | Fluid dispensing device |
Jul, 2028
(3 years from now) | |
| US8147461 | HALEON US HOLDINGS | Fluid dispensing device |
Oct, 2028
(3 years from now) | |
Drugs and Companies using FLUTICASONE FUROATE ingredient
Market Authorisation Date: 27 April, 2007
Treatment: NA
Dosage: SPRAY, METERED
More Information on Dosage
FLONASE SENSIMIST ALLERGY RELIEF family patents
70. Fruzaqla patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7829574 | TAKEDA PHARMS USA | Substituted quinazoline compounds and their use in treating angiogenesis-related diseases |
May, 2028
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8212033 | TAKEDA PHARMS USA | Use of substituted quinazoline compounds in treating angiogenesis-related diseases |
May, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 08, 2028 |
Drugs and Companies using FRUQUINTINIB ingredient
NCE-1 date: 09 November, 2027
Market Authorisation Date: 08 November, 2023
Treatment: Treatment of patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, anti-vegf therapy, and, if ras wild-ty...
Dosage: CAPSULE
More Information on Dosage
FRUZAQLA family patents
71. Galafold patent expiration
Can you believe GALAFOLD received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11033538 | AMICUS THERAP US | Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones |
Apr, 2028
(3 years from now) | |
| US10925866 | AMICUS THERAP US | Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones |
Apr, 2028
(3 years from now) | |
| US9999618 | AMICUS THERAP US | Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones |
Apr, 2028
(3 years from now) | |
| US10525045 | AMICUS THERAP US | Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones |
Apr, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 10, 2023 |
| Orphan Drug Exclusivity(ODE-205) | Aug 10, 2025 |
Drugs and Companies using MIGALASTAT HYDROCHLORIDE ingredient
NCE-1 date: 10 August, 2022
Market Authorisation Date: 10 August, 2018
Treatment: The treatment of fabry patients; A method of reducing left ventricular mass index (lvmi) in a fabry patient by administering migalastat
Dosage: CAPSULE
How can I launch a generic of GALAFOLD before it's drug patent expiration?
More Information on Dosage
GALAFOLD family patents
72. Givlaari patent expiration
Can you believe GIVLAARI received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10131907 | ALNYLAM PHARMS INC | Glycoconjugates of RNA interference agents |
Aug, 2028
(3 years from now) | |
| US8828956 | ALNYLAM PHARMS INC | Carbohydrate conjugates as delivery agents for oligonucleotides |
Dec, 2028
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 20, 2024 |
| Orphan Drug Exclusivity(ODE-273) | Nov 20, 2026 |
Drugs and Companies using GIVOSIRAN SODIUM ingredient
NCE-1 date: 21 November, 2023
Market Authorisation Date: 20 November, 2019
Treatment: Treatment of acute hepatic porphyria
Dosage: SOLUTION
More Information on Dosage
GIVLAARI family patents
73. Glyxambi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7579449 | BOEHRINGER INGELHEIM | Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture |
Aug, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Jan 30, 2018 |
| New Chemical Entity Exclusivity(NCE) | Aug 01, 2019 |
| New Indication(I-739) | Dec 02, 2019 |
| M(M-258) | Jul 03, 2022 |
| M(M-252) | Mar 30, 2023 |
Drugs and Companies using EMPAGLIFLOZIN; LINAGLIPTIN ingredient
NCE-1 date: 01 August, 2018
Market Authorisation Date: 30 January, 2015
Treatment: NA
Dosage: TABLET
How can I launch a generic of GLYXAMBI before it's drug patent expiration?
More Information on Dosage
GLYXAMBI family patents
74. Gocovri patent expiration
Can you believe GOCOVRI received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8389578 | SUPERNUS PHARMS | Composition and method for treating neurological disease |
Jan, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-769) | Aug 24, 2020 |
| New Product(NP) | Aug 24, 2020 |
| Orphan Drug Exclusivity(ODE) | Aug 24, 2024 |
| Orphan Drug Exclusivity(ODE-153) | Aug 24, 2024 |
Drugs and Companies using AMANTADINE HYDROCHLORIDE ingredient
Market Authorisation Date: 24 August, 2017
Treatment: Treatment of dyskinesia in patients with parkinson's disease receiving immediate release levodopa-based therapy, with or without concomitant dopaminergic medications
Dosage: CAPSULE, EXTENDED RELEASE
How can I launch a generic of GOCOVRI before it's drug patent expiration?
More Information on Dosage
GOCOVRI family patents
75. Harvoni patent expiration
HARVONI's oppositions filed in EPO
HARVONI IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8580765 | GILEAD SCIENCES INC | NA |
Mar, 2028
(3 years from now) | |
| US8334270 | GILEAD SCIENCES INC | NA |
Mar, 2028
(3 years from now) | |
| US9085573 | GILEAD SCIENCES INC | NA |
Mar, 2028
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8735372 | GILEAD SCIENCES INC | NA |
Mar, 2028
(3 years from now) | |
|
US9085573 (Pediatric) | GILEAD SCIENCES INC | NA |
Sep, 2028
(3 years from now) | |
|
US8735372 (Pediatric) | GILEAD SCIENCES INC | NA |
Sep, 2028
(3 years from now) | |
|
US8334270 (Pediatric) | GILEAD SCIENCES INC | NA |
Sep, 2028
(3 years from now) | |
|
US8580765 (Pediatric) | GILEAD SCIENCES INC | NA |
Sep, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosing Schedule(D-153) | Nov 12, 2018 |
| New Indication(I-718) | Nov 12, 2018 |
| New Indication(I-719) | Nov 12, 2018 |
| New Indication(I-720) | Nov 12, 2018 |
| New Dosing Schedule(D-158) | Feb 12, 2019 |
| New Dosing Schedule(D-159) | Feb 12, 2019 |
| New Dosing Schedule(D-160) | Feb 12, 2019 |
| New Chemical Entity Exclusivity(NCE) | Oct 10, 2019 |
| New Patient Population(NPP) | Apr 07, 2020 |
| New Dosing Schedule(D-177) | Nov 15, 2022 |
| Orphan Drug Exclusivity(ODE) | Apr 07, 2024 |
| ODE*(ODE*) | Aug 28, 2026 |
| Orphan Drug Exclusivity(ODE-136) | Apr 07, 2024 |
| Pediatric Exclusivity(PED) | Oct 07, 2024 |
| Orphan Drug Exclusivity(ODE-262) | Aug 28, 2026 |
| Orphan Drug Exclusivity(ODE-263) | Aug 28, 2026 |
| Orphan Drug Exclusivity(ODE-264) | Aug 28, 2026 |
Drugs and Companies using LEDIPASVIR; SOFOSBUVIR ingredient
NCE-1 date: 08 October, 2023
Market Authorisation Date: 28 August, 2019
Treatment: For the treatment of hepatitis c
Dosage: TABLET; PELLETS
More Information on Dosage
HARVONI family patents
76. Hemangeol patent expiration
HEMANGEOL's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8987262 | PIERRE FABRE | Use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas |
Oct, 2028
(3 years from now) | |
| US8338489 | PIERRE FABRE | Use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas |
Oct, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 14, 2017 |
| Orphan Drug Exclusivity(ODE) | Mar 14, 2021 |
| Orphan Drug Exclusivity(ODE-62) | Mar 14, 2021 |
Drugs and Companies using PROPRANOLOL HYDROCHLORIDE ingredient
Market Authorisation Date: 14 March, 2014
Treatment: Method to treat infantile hemangioma; Method to treat hemangioma.
Dosage: SOLUTION
How can I launch a generic of HEMANGEOL before it's drug patent expiration?
More Information on Dosage
HEMANGEOL family patents
77. Imbruvica patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8008309 (Pediatric) | PHARMACYCLICS LLC | Inhibitors of bruton's tyrosine kinase |
May, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-680) | Feb 12, 2017 |
| New Indication(I-689) | Jul 28, 2017 |
| New Indication(I-702) | Jan 29, 2018 |
| New Chemical Entity Exclusivity(NCE) | Nov 13, 2018 |
| New Indication(I-729) | Mar 04, 2019 |
| New Dosing Schedule(D-165) | May 06, 2019 |
| New Indication(I-736) | May 06, 2019 |
| New Indication(I-737) | May 06, 2019 |
| New Indication(I-741) | Jan 18, 2020 |
| New Indication(I-753) | Aug 02, 2020 |
| Orphan Drug Exclusivity(ODE-55) | Nov 13, 2020 |
| Orphan Drug Exclusivity(ODE-60) | Feb 12, 2021 |
| Orphan Drug Exclusivity(ODE-72) | Jul 28, 2021 |
| New Dosing Schedule(D-176) | Aug 24, 2021 |
| M(M-236) | Jan 25, 2022 |
| Orphan Drug Exclusivity(ODE-86) | Jan 29, 2022 |
| Orphan Drug Exclusivity(ODE-109) | Mar 04, 2023 |
| Orphan Drug Exclusivity(ODE-117) | May 06, 2023 |
| Orphan Drug Exclusivity(ODE-128) | Jan 18, 2024 |
| Orphan Drug Exclusivity(ODE) | Aug 02, 2024 |
| ODE*(ODE*) | Aug 02, 2024 |
| Orphan Drug Exclusivity(ODE-152) | Aug 02, 2024 |
| M(M-14) | Aug 24, 2025 |
| New Product(NP) | Aug 24, 2025 |
| New Patient Population(NPP) | Aug 24, 2025 |
| Pediatric Exclusivity(PED) | Feb 24, 2030 |
| Orphan Drug Exclusivity(ODE-405) | Aug 24, 2029 |
Drugs and Companies using IBRUTINIB ingredient
NCE-1 date: 24 February, 2025
Market Authorisation Date: 20 December, 2017
Treatment: NA
Dosage: TABLET; SUSPENSION; CAPSULE
How can I launch a generic of IMBRUVICA before it's drug patent expiration?
More Information on Dosage
IMBRUVICA family patents
78. Incivek patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8431615 | VERTEX PHARMS | Dose forms |
May, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 23, 2016 |
Drugs and Companies using TELAPREVIR ingredient
NCE-1 date: 24 May, 2015
Market Authorisation Date: 23 May, 2011
Treatment: Method of treating chronic hepatitis c
Dosage: TABLET
More Information on Dosage
INCIVEK family patents
79. Incruse Ellipta patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8161968 | GLAXO GRP ENGLAND | Medicament dispenser |
Feb, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 18, 2018 |
| M(M-172) | Feb 24, 2019 |
| M(M-245) | Jun 09, 2022 |
Drugs and Companies using UMECLIDINIUM BROMIDE ingredient
NCE-1 date: 18 December, 2017
Market Authorisation Date: 30 April, 2014
Treatment: NA
Dosage: POWDER
More Information on Dosage
INCRUSE ELLIPTA family patents
80. Injectafer patent expiration
INJECTAFER's oppositions filed in EPO
INJECTAFER IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7754702 | AM REGENT | Methods and compositions for administration of iron |
Feb, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jul 25, 2016 |
| New Strength(NS) | Apr 28, 2024 |
| New Patient Population(NPP) | Nov 19, 2024 |
| New Indication(I-915) | May 31, 2026 |
Drugs and Companies using FERRIC CARBOXYMALTOSE ingredient
Market Authorisation Date: 28 April, 2021
Treatment: Method of treating ida in adult patients with non-dialysis dependent chronic kidney disease & weighing at least 40 kg by intravenously administering ferric carboxymaltose to provide at least about 0.6...
Dosage: SOLUTION
How can I launch a generic of INJECTAFER before it's drug patent expiration?
More Information on Dosage
INJECTAFER family patents
81. Inpefa patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7781577 | LEXICON PHARMS INC | Inhibitors of sodium glucose co-transporter 2 and methods of their use |
May, 2028
(3 years from now) | |
| US8476413 | LEXICON PHARMS INC | Sulfanyl-tetrahydropyran-based compounds and methods of their use |
May, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 26, 2028 |
Drugs and Companies using SOTAGLIFLOZIN ingredient
NCE-1 date: 27 May, 2027
Market Authorisation Date: 26 May, 2023
Treatment: Reduction of risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure in adults with heart failure or type 2 diabetes mellitus, chronic kidney disease, and other cardi...
Dosage: TABLET
More Information on Dosage
INPEFA family patents
82. Inqovi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9567363 | OTSUKA | Certain compounds, compositions and methods |
Oct, 2028
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8618075 | OTSUKA | Certain compounds, compositions and methods |
Oct, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 07, 2025 |
| Orphan Drug Exclusivity(ODE-316) | Jul 07, 2027 |
Drugs and Companies using CEDAZURIDINE; DECITABINE ingredient
NCE-1 date: 07 July, 2024
Market Authorisation Date: 07 July, 2020
Treatment: Method for inhibiting degradation of a cda substrate by administering cedazuridine
Dosage: TABLET
More Information on Dosage
INQOVI family patents
83. Inrebic patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8138199 | BRISTOL-MYERS | Use of bi-aryl meta-pyrimidine inhibitors of kinases |
Jun, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 16, 2024 |
| Orphan Drug Exclusivity(ODE-259) | Aug 16, 2026 |
Drugs and Companies using FEDRATINIB HYDROCHLORIDE ingredient
NCE-1 date: 17 August, 2023
Market Authorisation Date: 16 August, 2019
Treatment: Treatment of adult patients with intermediate-2 or high-risk primary or secondary myelofibrosis
Dosage: CAPSULE
More Information on Dosage
INREBIC family patents
84. Intrarosa patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8629129 | MILLICENT | Pharmaceutical compositions |
Aug, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 16, 2021 |
Drugs and Companies using PRASTERONE ingredient
NCE-1 date: 16 November, 2020
Market Authorisation Date: 16 November, 2016
Treatment: NA
Dosage: INSERT
More Information on Dosage
INTRAROSA family patents
85. Isentress patent expiration
ISENTRESS's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8852632 | MSD SUB MERCK | Pharmaceutical formulation containing a release rate controlling composition |
Jan, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 12, 2012 |
| New Dosage Form(NDF) | Dec 20, 2016 |
| New Patient Population(NPP) | Nov 22, 2020 |
| M(M-114) | Mar 28, 2015 |
| New Dosing Schedule(D-167) | May 26, 2020 |
| Pediatric Exclusivity(PED) | May 22, 2021 |
Drugs and Companies using RALTEGRAVIR POTASSIUM ingredient
NCE-1 date: 22 May, 2020
Market Authorisation Date: 12 October, 2007
Treatment: Treatment of hiv infection
Dosage: TABLET
How can I launch a generic of ISENTRESS before it's drug patent expiration?
More Information on Dosage
ISENTRESS family patents
86. Jakafi patent expiration
JAKAFI's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8722693 | INCYTE CORP | Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
Jun, 2028
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8829013 | INCYTE CORP | Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
Jun, 2028
(3 years from now) | |
| US10016429 | INCYTE CORP | Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
Jun, 2028
(3 years from now) | |
| US8822481 | INCYTE CORP | Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d] pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
Jun, 2028
(3 years from now) | |
|
US8415362 (Pediatric) | INCYTE CORP | Pyrazolyl substituted pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors |
Jun, 2028
(3 years from now) | |
|
US7598257 (Pediatric) | INCYTE CORP | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors |
Jun, 2028
(3 years from now) | |
|
US8722693 (Pediatric) | INCYTE CORP | Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
Dec, 2028
(4 years from now) | |
|
US10016429 (Pediatric) | INCYTE CORP | Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
Dec, 2028
(4 years from now) | |
|
US8829013 (Pediatric) | INCYTE CORP | Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
Dec, 2028
(4 years from now) | |
|
US8822481 (Pediatric) | INCYTE CORP | Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d] pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
Dec, 2028
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 16, 2016 |
| New Indication(I-699) | Dec 04, 2017 |
| Orphan Drug Exclusivity(ODE) | Nov 16, 2018 |
| Orphan Drug Exclusivity(ODE-19) | Nov 16, 2018 |
| Orphan Drug Exclusivity(ODE-79) | Dec 04, 2021 |
| New Indication(I-799) | May 24, 2022 |
| New Indication(I-872) | Sep 22, 2024 |
| M(M-285) | Dec 19, 2025 |
| Orphan Drug Exclusivity(ODE-238) | May 24, 2026 |
| Orphan Drug Exclusivity(ODE-373) | Sep 22, 2028 |
| Pediatric Exclusivity(PED) | Mar 22, 2029 |
Drugs and Companies using RUXOLITINIB PHOSPHATE ingredient
NCE-1 date: 22 March, 2028
Market Authorisation Date: 16 November, 2011
Treatment: For treatment of intermediate or high-risk myelofibrosis (mf), including primary mf, post-polycythemia vera mf and post-essential thrombocythemia mf; For treatment of steroid-refractory acute graft-ve...
Dosage: TABLET
How can I launch a generic of JAKAFI before it's drug patent expiration?
More Information on Dosage
JAKAFI family patents
87. Janumet patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8414921 | MSD SUB MERCK | Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with metformin |
Jul, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 16, 2011 |
| M(M-244) | Aug 12, 2022 |
| M(M-187) | Dec 04, 2023 |
| Pediatric Exclusivity(PED) | Jun 04, 2024 |
Drugs and Companies using METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE ingredient
NCE-1 date: 05 June, 2023
Market Authorisation Date: 30 March, 2007
Treatment: Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-4 inhibitor in combination with insulin
Dosage: TABLET
How can I launch a generic of JANUMET before it's drug patent expiration?
More Information on Dosage
JANUMET family patents
88. Jardiance patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7579449 | BOEHRINGER INGELHEIM | Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture |
Aug, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-159) | Jun 26, 2018 |
| M(M-160) | Jun 26, 2018 |
| M(M-161) | Jun 26, 2018 |
| M(M-174) | Mar 18, 2019 |
| New Chemical Entity Exclusivity(NCE) | Aug 01, 2019 |
| New Indication(I-739) | Dec 02, 2019 |
| New Indication(I-869) | Aug 18, 2024 |
| M(M-82) | Feb 24, 2025 |
| Pediatric Exclusivity(PED) | Dec 20, 2026 |
| New Patient Population(NPP) | Jun 20, 2026 |
| New Indication(I-922) | Sep 21, 2026 |
Drugs and Companies using EMPAGLIFLOZIN ingredient
NCE-1 date: 20 December, 2025
Market Authorisation Date: 01 August, 2014
Treatment: NA
Dosage: TABLET
How can I launch a generic of JARDIANCE before it's drug patent expiration?
More Information on Dosage
JARDIANCE family patents
89. Jesduvroq patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8324208 | GLAXOSMITHKLINE | Prolyl hydroxylase inhibitors |
Dec, 2028
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 01, 2028 |
Drugs and Companies using DAPRODUSTAT ingredient
NCE-1 date: 01 February, 2027
Market Authorisation Date: 01 February, 2023
Treatment: NA
Dosage: TABLET
More Information on Dosage
JESDUVROQ family patents
90. Jublia patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10828369 | BAUSCH | Compositions and methods for treating diseases of the nail |
Jan, 2028
(3 years from now) | |
| US11213519 | BAUSCH | Compositions and methods for treating diseases of the nail |
Jan, 2028
(3 years from now) | |
| US10512640 | BAUSCH | Compositions and methods for treating diseases of the nail |
Jan, 2028
(3 years from now) | |
| US9877955 | BAUSCH | Compositions and methods for treating diseases of the nail |
Jan, 2028
(3 years from now) | |
| US11872218 | BAUSCH | Compositions and methods for treating diseases of the nail |
Jan, 2028
(3 years from now) | |
| US9566272 | BAUSCH | Compositions and methods for treating diseases of the nail |
Jan, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 06, 2019 |
| New Patient Population(NPP) | Apr 27, 2023 |
Drugs and Companies using EFINACONAZOLE ingredient
NCE-1 date: 06 June, 2018
Market Authorisation Date: 06 June, 2014
Treatment: Antimycotic uses, specifically treatment of onychomycosis; Topical treatment of the toenail(s) due to trichophyton rubrum and trichophyton mentagrophytes; Topical treatment of onychomycosis of the toe...
Dosage: SOLUTION
How can I launch a generic of JUBLIA before it's drug patent expiration?
More Information on Dosage
JUBLIA family patents
91. Juluca patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8129385 (Pediatric) | VIIV HLTHCARE | Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness |
Apr, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 12, 2018 |
| New Combination(NC) | Nov 21, 2020 |
Drugs and Companies using DOLUTEGRAVIR SODIUM; RILPIVIRINE HYDROCHLORIDE ingredient
NCE-1 date: 12 August, 2017
Market Authorisation Date: 21 November, 2017
Treatment: NA
Dosage: TABLET
How can I launch a generic of JULUCA before it's drug patent expiration?
More Information on Dosage
JULUCA family patents
92. Kaletra patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8377952 (Pediatric) | ABBVIE | Solid pharmaceutical dosage formulation |
Apr, 2028
(3 years from now) | |
|
US8025899 (Pediatric) | ABBVIE | Solid pharmaceutical dosage form |
Jun, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosing Schedule(D-124) | Apr 27, 2013 |
Drugs and Companies using LOPINAVIR; RITONAVIR ingredient
Market Authorisation Date: 09 November, 2007
Treatment: NA
Dosage: TABLET
How can I launch a generic of KALETRA before it's drug patent expiration?
More Information on Dosage
KALETRA family patents
93. Kazano patent expiration
Can you believe KAZANO received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7807689 | TAKEDA PHARMS USA | Dipeptidyl peptidase inhibitors |
Jun, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Jan 25, 2016 |
| New Chemical Entity Exclusivity(NCE) | Jan 25, 2018 |
| M(M-177) | Apr 05, 2019 |
| M(M-300) | Jul 27, 2026 |
Drugs and Companies using ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE ingredient
NCE-1 date: 25 January, 2017
Market Authorisation Date: 25 January, 2013
Treatment: Method of treating diabetes comprising administering alogliptin
Dosage: TABLET
How can I launch a generic of KAZANO before it's drug patent expiration?
More Information on Dosage
KAZANO family patents
94. Keppra Xr patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7858122 | UCB INC | Extended release formulation of levetiracetam |
Sep, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Sep 12, 2011 |
Drugs and Companies using LEVETIRACETAM ingredient
Market Authorisation Date: 12 September, 2008
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE
How can I launch a generic of KEPPRA XR before it's drug patent expiration?
More Information on Dosage
KEPPRA XR family patents
95. Kisqali patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8324225 | NOVARTIS | Pyrrolopyrimidine compounds and their uses |
Jun, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-783) | Jul 18, 2021 |
| New Indication(I-784) | Jul 18, 2021 |
| New Chemical Entity Exclusivity(NCE) | Mar 13, 2022 |
| New Patient Population(NPP) | Dec 10, 2024 |
| New Indication(I-950) | Sep 17, 2027 |
Drugs and Companies using RIBOCICLIB SUCCINATE ingredient
NCE-1 date: 13 March, 2021
Market Authorisation Date: 13 March, 2017
Treatment: NA
Dosage: TABLET
How can I launch a generic of KISQALI before it's drug patent expiration?
More Information on Dosage
KISQALI family patents
96. Kisqali Femara Co-pack (copackaged) patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8324225 | NOVARTIS | Pyrrolopyrimidine compounds and their uses |
Jun, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 13, 2022 |
| New Patient Population(NPP) | Dec 10, 2024 |
| New Indication(I-951) | Sep 17, 2027 |
Drugs and Companies using LETROZOLE; RIBOCICLIB SUCCINATE ingredient
NCE-1 date: 13 March, 2021
Market Authorisation Date: 04 May, 2017
Treatment: NA
Dosage: TABLET
How can I launch a generic of KISQALI FEMARA CO-PACK (COPACKAGED) before it's drug patent expiration?
More Information on Dosage
KISQALI FEMARA CO-PACK (COPACKAGED) family patents
97. Korlym patent expiration
KORLYM IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8921348 | CORCEPT THERAP | Optimizing mifepristone levels in plasma serum of patients suffering from mental disorders treatable with glucocorticoid receptor antagonists |
Aug, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Feb 17, 2015 |
| Orphan Drug Exclusivity(ODE) | Feb 17, 2019 |
| Orphan Drug Exclusivity(ODE-22) | Feb 17, 2019 |
Drugs and Companies using MIFEPRISTONE ingredient
Market Authorisation Date: 17 February, 2012
Treatment: Treating cushing's syndrome
Dosage: TABLET
How can I launch a generic of KORLYM before it's drug patent expiration?
More Information on Dosage
KORLYM family patents
98. Kybella patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8242294 | ABBVIE | Synthetic bile acid compositions and methods |
May, 2028
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9636349 | ABBVIE | Synthetic bile acid compositions and methods |
Feb, 2028
(3 years from now) | |
| US9522155 | ABBVIE | Synthetic bile acid compositions and methods |
Feb, 2028
(3 years from now) | |
| US8461140 | ABBVIE | Synthetic bile acid compositions and methods |
Feb, 2028
(3 years from now) | |
| US9949986 | ABBVIE | Synthetic bile acid compositions and methods |
Feb, 2028
(3 years from now) | |
| US8546367 | ABBVIE | Synthetic bile acid compositions and methods |
Feb, 2028
(3 years from now) | |
| US8883770 | ABBVIE | Synthetic bile acid compositions and methods |
Feb, 2028
(3 years from now) | |
Drugs and Companies using DEOXYCHOLIC ACID ingredient
Market Authorisation Date: 29 April, 2015
Treatment: Improvement in the appearance of moderate to severe convexity or fullness associated with submental fat in adults by means of reducing submental fat volume as described in the approved labeling; Metho...
Dosage: SOLUTION
How can I launch a generic of KYBELLA before it's drug patent expiration?
More Information on Dosage
KYBELLA family patents
99. Lamictal Odt patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9339504 | GLAXOSMITHKLINE LLC | Orally disintegrating tablet compositions of lamotrigine |
Jul, 2028
(3 years from now) | |
| US8840925 | GLAXOSMITHKLINE LLC | Orally disintegrating tablet compositions of lamotrigine |
Jul, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-159) | May 18, 2018 |
Drugs and Companies using LAMOTRIGINE ingredient
Market Authorisation Date: 08 May, 2009
Treatment: Lamictal is an antiepileptic drug (aed) indicated for: epilepsy-adjunctive therapy in patients greater than or equal to 2 years of age: (1.1) partial seizures primary generalized tonic-clonic seizures
Dosage: TABLET, ORALLY DISINTEGRATING
How can I launch a generic of LAMICTAL ODT before it's drug patent expiration?
More Information on Dosage
LAMICTAL ODT family patents
100. Lamictal Xr patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8637512 | GLAXOSMITHKLINE LLC | Formulations and method of treatment |
Jun, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | May 29, 2012 |
| Pediatric Exclusivity(PED) | Nov 29, 2012 |
| New Indication(I-622) | Jan 29, 2013 |
| New Indication(I-644) | Apr 25, 2014 |
Drugs and Companies using LAMOTRIGINE ingredient
Market Authorisation Date: 29 May, 2009
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE
How can I launch a generic of LAMICTAL XR before it's drug patent expiration?
More Information on Dosage
LAMICTAL XR family patents
101. Lantus patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7918833 (Pediatric) | SANOFI AVENTIS US | Pen-type injector |
Mar, 2028
(3 years from now) | |
Drugs and Companies using INSULIN GLARGINE RECOMBINANT ingredient
Market Authorisation Date: 27 April, 2007
Treatment: NA
Dosage: INJECTABLE
More Information on Dosage
LANTUS family patents
102. Lenvima patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US9006256 (Pediatric) | EISAI INC | Antitumor agent for thyroid cancer |
Jan, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-734) | May 13, 2019 |
| New Chemical Entity Exclusivity(NCE) | Feb 13, 2020 |
| New Indication(I-787) | Aug 15, 2021 |
| Orphan Drug Exclusivity(ODE) | Feb 13, 2022 |
| Orphan Drug Exclusivity(ODE-87) | Feb 13, 2022 |
| New Indication(I-807) | Sep 17, 2022 |
| M(M-269) | Jul 21, 2024 |
| New Indication(I-868) | Aug 10, 2024 |
| M(M-272) | Dec 19, 2024 |
| Orphan Drug Exclusivity(ODE-196) | Aug 15, 2025 |
| M(M-14) | Apr 03, 2027 |
| Pediatric Exclusivity(PED) | Oct 03, 2027 |
Drugs and Companies using LENVATINIB MESYLATE ingredient
NCE-1 date: 03 October, 2026
Market Authorisation Date: 13 February, 2015
Treatment: NA
Dosage: CAPSULE
How can I launch a generic of LENVIMA before it's drug patent expiration?
More Information on Dosage
LENVIMA family patents
103. Leqvio patent expiration
Can you believe LEQVIO received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10131907 | NOVARTIS | Glycoconjugates of RNA interference agents |
Aug, 2028
(3 years from now) | |
| US9370582 | NOVARTIS | Carbohydrate conjugates as delivery agents for oligonucleotides |
Dec, 2028
(4 years from now) | |
| US8828956 | NOVARTIS | Carbohydrate conjugates as delivery agents for oligonucleotides |
Dec, 2028
(4 years from now) | |
| US10806791 | NOVARTIS | Carbohydrate conjugates as delivery agents for oligonucleotides |
Dec, 2028
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 22, 2026 |
Drugs and Companies using INCLISIRAN SODIUM ingredient
NCE-1 date: 22 December, 2025
Market Authorisation Date: 22 December, 2021
Treatment: As an adjunct to diet and statin therapy for the treatment of adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (hefh), by inhibiting expression of the pcsk9 gen...
Dosage: SOLUTION
More Information on Dosage
LEQVIO family patents
104. Locametz patent expiration
LOCAMETZ's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11369590 | NOVARTIS | PSMA binding ligand-linker conjugates and methods for using |
Aug, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 23, 2025 |
Drugs and Companies using GALLIUM GA-68 GOZETOTIDE ingredient
Market Authorisation Date: 23 March, 2022
Treatment: For use after radiolabeling with gallium-68, for positron emission tomography of prostate-specific membrane antigen (psma)-positive lesions in men with prostate cancer
Dosage: POWDER
More Information on Dosage
LOCAMETZ family patents
105. Lonhala Magnair Kit patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9265900 | SUMITOMO PHARMA AM | Disposable ampoule for an aerosol generating device |
Dec, 2028
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Dec 05, 2020 |
Drugs and Companies using GLYCOPYRROLATE ingredient
Market Authorisation Date: 05 December, 2017
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
LONHALA MAGNAIR KIT family patents
106. Loseasonique patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7855190 | TEVA BRANDED PHARM | Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration |
Dec, 2028
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 24, 2011 |
Drugs and Companies using ETHINYL ESTRADIOL; LEVONORGESTREL ingredient
Market Authorisation Date: 24 October, 2008
Treatment: Prevention of pregnancy
Dosage: TABLET
How can I launch a generic of LOSEASONIQUE before it's drug patent expiration?
More Information on Dosage
LOSEASONIQUE family patents
107. Lupron Depot patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9617303 | ABBVIE ENDOCRINE INC | Sustained-release composition and method for producing the same |
Mar, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosing Schedule(D-132) | Jun 17, 2014 |
| New Strength(NS) | Jun 17, 2014 |
Drugs and Companies using LEUPROLIDE ACETATE ingredient
Market Authorisation Date: 22 December, 1995
Treatment: Treatment of advanced prostatic cancer
Dosage: INJECTABLE
How can I launch a generic of LUPRON DEPOT before it's drug patent expiration?
More Information on Dosage
LUPRON DEPOT family patents
108. Lupron Depot-ped Kit patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9617303 | ABBVIE ENDOCRINE INC | Sustained-release composition and method for producing the same |
Mar, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Aug 15, 2014 |
| M(M-107) | Oct 08, 2014 |
| New Strength(NS) | Apr 14, 2026 |
Drugs and Companies using LEUPROLIDE ACETATE ingredient
Market Authorisation Date: 16 April, 1993
Treatment: Treatment of pediatric patients with central precocious puberty
Dosage: POWDER
More Information on Dosage
LUPRON DEPOT-PED KIT family patents
109. Lynparza patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8247416 | ASTRAZENECA | Phthalazinone derivative |
Sep, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 19, 2019 |
| New Product(NP) | Aug 17, 2020 |
| New Indication(I-762) | Jan 12, 2021 |
| New Indication(I-776) | Dec 19, 2021 |
| Orphan Drug Exclusivity(ODE) | Dec 19, 2021 |
| Orphan Drug Exclusivity(ODE-83) | Dec 19, 2021 |
| New Indication(I-818) | Dec 27, 2022 |
| New Indication(I-831) | May 08, 2023 |
| New Indication(I-832) | May 19, 2023 |
| Orphan Drug Exclusivity(ODE-180) | Aug 17, 2024 |
| Orphan Drug Exclusivity(ODE-181) | Aug 17, 2024 |
| New Indication(I-885) | Mar 11, 2025 |
| Orphan Drug Exclusivity(ODE-226) | Dec 19, 2025 |
| New Indication(I-914) | May 31, 2026 |
| Orphan Drug Exclusivity(ODE-283) | Dec 27, 2026 |
| Orphan Drug Exclusivity(ODE-306) | May 08, 2027 |
Drugs and Companies using OLAPARIB ingredient
NCE-1 date: 19 December, 2018
Market Authorisation Date: 19 December, 2014
Treatment: NA
Dosage: CAPSULE
How can I launch a generic of LYNPARZA before it's drug patent expiration?
More Information on Dosage
LYNPARZA family patents
110. Mayzent patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7939519 | NOVARTIS | Immunosuppresant compounds and compositions |
Aug, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 26, 2024 |
| M(M-274) | Mar 01, 2025 |
Drugs and Companies using SIPONIMOD ingredient
NCE-1 date: 27 March, 2023
Market Authorisation Date: 26 March, 2019
Treatment: NA
Dosage: TABLET
How can I launch a generic of MAYZENT before it's drug patent expiration?
More Information on Dosage
MAYZENT family patents
111. Minivelle patent expiration
MINIVELLE's oppositions filed in EPO
MINIVELLE IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9724310 | NOVEN | Transdermal estrogen device and delivery |
Jul, 2028
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9833419 | NOVEN | Transdermal estrogen device and delivery |
Jul, 2028
(3 years from now) | |
| US9730900 | NOVEN | Transdermal estrogen device and delivery |
Jul, 2028
(3 years from now) | |
Drugs and Companies using ESTRADIOL ingredient
Market Authorisation Date: 23 September, 2014
Treatment: A method for administering estradiol comprising a monolithic transdermal drug delivery system consisting of (i) a backing layer and (ii) a single adhesive polymer matrix layer as claimed in us patent ...
Dosage: FILM, EXTENDED RELEASE
How can I launch a generic of MINIVELLE before it's drug patent expiration?
More Information on Dosage
MINIVELLE family patents
112. Mirapex Er patent expiration
MIRAPEX ER's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7695734 | BOEHRINGER INGELHEIM | Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof |
Apr, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Feb 19, 2013 |
| New Indication(I-623) | Mar 19, 2013 |
Drugs and Companies using PRAMIPEXOLE DIHYDROCHLORIDE ingredient
Market Authorisation Date: 19 February, 2010
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE
How can I launch a generic of MIRAPEX ER before it's drug patent expiration?
More Information on Dosage
MIRAPEX ER family patents
113. Mitosol patent expiration
Can you believe MITOSOL received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9539241 | MOBIUS THERAP | Apparatus and method for reconstituting a pharmaceutical and preparing the reconstituted pharmaceutical for transient application |
Jan, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | Feb 07, 2019 |
| Orphan Drug Exclusivity(ODE-21) | Feb 07, 2019 |
Drugs and Companies using MITOMYCIN ingredient
Market Authorisation Date: 07 February, 2012
Treatment: Mitosol is an antimetabolite indicated as an adjunct to ab externo glaucoma surgery. it is intended for topical application to the site of glaucoma filtration surgery
Dosage: FOR SOLUTION
More Information on Dosage
MITOSOL family patents
114. Morphabond Er patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7955619 | OHEMO LIFE | Abuse resistant drugs, method of use and method of making |
Aug, 2028
(3 years from now) | |
| US10314788 | OHEMO LIFE | Pharmaceutical compositions configured to deter dosage form splitting |
Aug, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-189) | Oct 02, 2018 |
Drugs and Companies using MORPHINE SULFATE ingredient
Market Authorisation Date: 02 October, 2015
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE
How can I launch a generic of MORPHABOND ER before it's drug patent expiration?
More Information on Dosage
MORPHABOND ER family patents
115. Movantik patent expiration
MOVANTIK's oppositions filed in EPO
MOVANTIK IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7786133 | VALINOR | Chemically modified small molecules |
Sep, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 16, 2019 |
Drugs and Companies using NALOXEGOL OXALATE ingredient
NCE-1 date: 16 September, 2018
Market Authorisation Date: 16 September, 2014
Treatment: NA
Dosage: TABLET
How can I launch a generic of MOVANTIK before it's drug patent expiration?
More Information on Dosage
MOVANTIK family patents
116. Mulpleta patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8889722 | VANCOCIN ITALIA | Pharmaceutical composition containing optically active compound having thrombopoietin receptor agonist activity, and intermediate therefor |
Jul, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 31, 2023 |
Drugs and Companies using LUSUTROMBOPAG ingredient
NCE-1 date: 31 July, 2022
Market Authorisation Date: 31 July, 2018
Treatment: NA
Dosage: TABLET
More Information on Dosage
MULPLETA family patents
117. Myrbetriq patent expiration
MYRBETRIQ's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8772315 | APGDI | Pharmaceutical composition for treating overactive bladder |
Oct, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 28, 2017 |
| New Indication(I-777) | Apr 27, 2021 |
| New Indication(I-855) | Mar 25, 2024 |
| Pediatric Exclusivity(PED) | Sep 25, 2024 |
Drugs and Companies using MIRABEGRON ingredient
NCE-1 date: 26 September, 2023
Market Authorisation Date: 28 June, 2012
Treatment: Use in combination with the muscarinic antagonist solifenacin succinate for the treatment of overactive bladder (oab) with symptoms of urge urinary incontinence, urgency, and urinary frequency
Dosage: TABLET, EXTENDED RELEASE
How can I launch a generic of MYRBETRIQ before it's drug patent expiration?
More Information on Dosage
MYRBETRIQ family patents
118. Naloxone Hydrochloride (autoinjector) patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7947017 | KALEO INC | Devices, systems and methods for medicament delivery |
Mar, 2028
(3 years from now) | |
Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 28 February, 2022
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
NALOXONE HYDROCHLORIDE (AUTOINJECTOR) family patents
119. Natazia patent expiration
NATAZIA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8153616 | BAYER HLTHCARE | Combination preparation for oral contraception and oral therapy of dysfunctional uterine bleeding containing estradiol valerate and dienogest and method of using same |
Jan, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 06, 2013 |
| New Indication(I-648) | Mar 14, 2015 |
Drugs and Companies using DIENOGEST; ESTRADIOL VALERATE ingredient
Market Authorisation Date: 06 May, 2010
Treatment: Treatment of heavy menstrual bleeding in women without organic pathology who choose to use an oral contraceptive as their method of contraception
Dosage: TABLET
How can I launch a generic of NATAZIA before it's drug patent expiration?
More Information on Dosage
NATAZIA family patents
120. Nayzilam patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9289432 | UCB INC | Methods and compositions for the delivery of a therapeutic agent |
Jan, 2028
(3 years from now) | |
| US8217033 | UCB INC | Methods and compositions for the delivery of a therapeutic agent |
Jan, 2028
(3 years from now) | |
| US9687495 | UCB INC | Methods and systems for the delivery of a therapeutic agent |
Jan, 2028
(3 years from now) | |
| US8809322 | UCB INC | Methods and compositions for the delivery of a therapeutic agent |
Jan, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 21, 2022 |
| Orphan Drug Exclusivity(ODE-243) | May 17, 2026 |
Drugs and Companies using MIDAZOLAM ingredient
Market Authorisation Date: 17 May, 2019
Treatment: Acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patient's usual seizure pattern in patie...
Dosage: SPRAY
How can I launch a generic of NAYZILAM before it's drug patent expiration?
More Information on Dosage
NAYZILAM family patents
121. Nerlynx patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10035788 | PUMA BIOTECH | Maleate salts of (E)-N-{4[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
Oct, 2028
(3 years from now) | |
| US9139558 | PUMA BIOTECH | Maleate salts of (E)-N-{4-[3-Chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
Oct, 2028
(3 years from now) | |
| US9630946 | PUMA BIOTECH | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
Oct, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 17, 2022 |
| New Indication(I-823) | Feb 25, 2023 |
| New Dosing Schedule(D-182) | Jun 28, 2024 |
Drugs and Companies using NERATINIB MALEATE ingredient
NCE-1 date: 17 July, 2021
Market Authorisation Date: 17 July, 2017
Treatment: Extended adjuvant treatment of adult patients with early-stage human epidermal growth factor receptor 2 (her2)-positive breast cancer, to follow adjuvant trastuzumab based therapy; Extended adjuvant t...
Dosage: TABLET
How can I launch a generic of NERLYNX before it's drug patent expiration?
More Information on Dosage
NERLYNX family patents
122. Nesina patent expiration
Can you believe NESINA received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7807689 | TAKEDA PHARMS USA | Dipeptidyl peptidase inhibitors |
Jun, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 25, 2018 |
| M(M-177) | Apr 05, 2019 |
| M(M-300) | Jul 27, 2026 |
Drugs and Companies using ALOGLIPTIN BENZOATE ingredient
NCE-1 date: 25 January, 2017
Market Authorisation Date: 25 January, 2013
Treatment: Method of treating diabetes comprising administering alogliptin
Dosage: TABLET
How can I launch a generic of NESINA before it's drug patent expiration?
More Information on Dosage
NESINA family patents
123. Nexavar patent expiration
NEXAVAR's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9737488 | BAYER HLTHCARE | Pharmaceutical composition for the treatment of cancer |
Sep, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | Dec 20, 2012 |
| New Indication(I-677) | Nov 22, 2016 |
| Orphan Drug Exclusivity(ODE-56) | Nov 22, 2020 |
Drugs and Companies using SORAFENIB TOSYLATE ingredient
Market Authorisation Date: 20 December, 2005
Treatment: Treatment of unresectable hepatocellular carcinoma
Dosage: TABLET
How can I launch a generic of NEXAVAR before it's drug patent expiration?
More Information on Dosage
NEXAVAR family patents
124. Nicorette patent expiration
NICORETTE's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8323683 | HALEON US HOLDINGS | Flavoring of drug-containing chewing gums |
Apr, 2028
(3 years from now) | |
Drugs and Companies using NICOTINE POLACRILEX ingredient
Market Authorisation Date: 09 February, 1996
Treatment: NA
Dosage: GUM, CHEWING
How can I launch a generic of NICORETTE before it's drug patent expiration?
More Information on Dosage
NICORETTE family patents
125. Nourianz patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7727993 | KYOWA KIRIN | Administering adenosine A2A receptor antagonist to reduce or suppress side effects of parkinson's disease therapy |
Jan, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 27, 2024 |
Drugs and Companies using ISTRADEFYLLINE ingredient
NCE-1 date: 28 August, 2023
Market Authorisation Date: 27 August, 2019
Treatment: A method of reducing off time from l-dopa therapy, comprising administering, to a human patient with parkinson's disease, an effective amount of istradefylline, wherein the patient currently receives ...
Dosage: TABLET
More Information on Dosage
NOURIANZ family patents
126. Nucynta Er patent expiration
NUCYNTA ER's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11344512 | COLLEGIUM PHARM INC | Titration of tapentadol |
Apr, 2028
(3 years from now) | |
| US8536130 | COLLEGIUM PHARM INC | Use of 1 phenyl-3-dimethylamino-propane compounds for treating neuropathic pain |
Sep, 2028
(3 years from now) | |
|
US11344512 (Pediatric) | COLLEGIUM PHARM INC | Titration of tapentadol |
Oct, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 20, 2013 |
| New Dosage Form(NDF) | Aug 25, 2014 |
| New Indication(I-656) | Aug 28, 2015 |
Drugs and Companies using TAPENTADOL HYDROCHLORIDE ingredient
NCE-1 date: 20 November, 2012
Market Authorisation Date: 25 August, 2011
Treatment: A method of titrating an opioid to manage neuropathic pain associated with diabetic peripheral neuropathy severe enough to require daily, around-the-clock, long-term opioid treatment and for which alt...
Dosage: TABLET, EXTENDED RELEASE
How can I launch a generic of NUCYNTA ER before it's drug patent expiration?
More Information on Dosage
NUCYNTA ER family patents
127. Nuplazid patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7732615 | ACADIA PHARMS INC | N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms |
Jun, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 29, 2021 |
Drugs and Companies using PIMAVANSERIN TARTRATE ingredient
NCE-1 date: 29 April, 2020
Market Authorisation Date: 28 June, 2018
Treatment: NA
Dosage: TABLET; CAPSULE
How can I launch a generic of NUPLAZID before it's drug patent expiration?
More Information on Dosage
NUPLAZID family patents
128. Nuvessa patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8877792 | CHEMO RESEARCH SL | Compositions for increasing solubility of azole drug compounds that are poorly soluble in water |
Feb, 2028
(3 years from now) | |
| US7893097 | CHEMO RESEARCH SL | Methods and compositions for increasing solubility of azole drug compounds that are poorly soluble in water |
Feb, 2028
(3 years from now) | |
| US8658678 | CHEMO RESEARCH SL | Methods and compositions for increasing solubility of azole drug compounds that are poorly soluble in water |
Jun, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 24, 2017 |
Drugs and Companies using METRONIDAZOLE ingredient
Market Authorisation Date: 24 March, 2014
Treatment: Treatment of bacterial vaginosis
Dosage: GEL
How can I launch a generic of NUVESSA before it's drug patent expiration?
More Information on Dosage
NUVESSA family patents
129. Ofirmev patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10383834 | MALLINCKRODT HOSP | Reduced dose intravenous acetaminophen |
Nov, 2028
(4 years from now) | |
| US9987238 | MALLINCKRODT HOSP | Reduced dose intravenous acetaminophen |
Nov, 2028
(4 years from now) | |
| US9610265 | MALLINCKRODT HOSP | Reduced dose intravenous acetaminophen |
Nov, 2028
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Nov 02, 2013 |
| M(M-196) | Jan 27, 2020 |
| Pediatric Exclusivity(PED) | Jul 27, 2020 |
Drugs and Companies using ACETAMINOPHEN ingredient
Market Authorisation Date: 02 November, 2010
Treatment: Modified dosing regimen for the management of mild to moderate pain; Modified dosing regimen for the management of mild to moderate pain or management of moderate to severe pain as an adjunct to opioi...
Dosage: SOLUTION
How can I launch a generic of OFIRMEV before it's drug patent expiration?
More Information on Dosage
OFIRMEV family patents
130. Olux E patent expiration
OLUX E's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8460641 | NORVIUM BIOSCIENCE | Microemulsion process and composition |
Nov, 2028
(3 years from now) | |
Drugs and Companies using CLOBETASOL PROPIONATE ingredient
Market Authorisation Date: 12 January, 2007
Treatment: Treatment of corticosteroid-responsive dermatoses
Dosage: AEROSOL, FOAM
How can I launch a generic of OLUX E before it's drug patent expiration?
More Information on Dosage
OLUX E family patents
131. Omnaris patent expiration
OMNARIS's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8371292 | COVIS | Use of ciclesonide for the treatment of respiratory diseases |
Feb, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 20, 2011 |
Drugs and Companies using CICLESONIDE ingredient
NCE-1 date: 20 October, 2010
Market Authorisation Date: 20 October, 2006
Treatment: Treatment of nasal symptoms associated with seasonal allergic rhinitis in adults and children 6 years of age and older. treatment of nasal symptoms associated w perennial allergic rhinitis in adults a...
Dosage: SPRAY, METERED
How can I launch a generic of OMNARIS before it's drug patent expiration?
More Information on Dosage
OMNARIS family patents
132. Onglyza patent expiration
ONGLYZA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7951400 | ASTRAZENECA AB | Coated tablet formulation and method |
Nov, 2028
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 31, 2014 |
| M(M-108) | Dec 16, 2014 |
| M(M-134) | May 24, 2016 |
| M(M-175) | Apr 05, 2019 |
| M(M-198) | Feb 27, 2020 |
Drugs and Companies using SAXAGLIPTIN HYDROCHLORIDE ingredient
NCE-1 date: 31 July, 2013
Market Authorisation Date: 31 July, 2009
Treatment: NA
Dosage: TABLET
How can I launch a generic of ONGLYZA before it's drug patent expiration?
More Information on Dosage
ONGLYZA family patents
133. Onivyde patent expiration
ONIVYDE's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8147867 | IPSEN | Liposomes useful for drug delivery |
Aug, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 22, 2018 |
| Orphan Drug Exclusivity(ODE) | Oct 22, 2022 |
| Orphan Drug Exclusivity(ODE-99) | Oct 22, 2022 |
| New Indication(I-932) | Feb 13, 2027 |
| Orphan Drug Exclusivity(ODE-463) | Feb 13, 2031 |
Drugs and Companies using IRINOTECAN HYDROCHLORIDE ingredient
Market Authorisation Date: 22 October, 2015
Treatment: NA
Dosage: INJECTABLE, LIPOSOMAL
More Information on Dosage
ONIVYDE family patents
134. Onmel patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8486456 | SEBELA IRELAND LTD | Itraconazole compositions with improved bioavailability |
Oct, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Apr 29, 2013 |
Drugs and Companies using ITRACONAZOLE ingredient
Market Authorisation Date: 29 April, 2010
Treatment: Onychomycosis of the toenail caused by tricophyton rubrum or trichophyton mentagrophytes, once daily use for 12 consecutive weeks
Dosage: TABLET
More Information on Dosage
ONMEL family patents
135. Onzetra Xsail patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8875704 | CURRAX | Nasal administration |
Apr, 2028
(3 years from now) | |
| US10722667 | CURRAX | Nasal administration |
Dec, 2028
(4 years from now) | |
Drugs and Companies using SUMATRIPTAN SUCCINATE ingredient
Market Authorisation Date: 27 January, 2016
Treatment: Method of drug delivery via the nasal cavity
Dosage: POWDER
More Information on Dosage
ONZETRA XSAIL family patents
136. Opsumit patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8367685 | ACTELION | Stable pharmaceutical compositions comprising a pyrimidine-sulfamide |
Oct, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 18, 2018 |
| Orphan Drug Exclusivity(ODE) | Oct 18, 2020 |
| Orphan Drug Exclusivity(ODE-54) | Oct 18, 2020 |
Drugs and Companies using MACITENTAN ingredient
NCE-1 date: 18 October, 2017
Market Authorisation Date: 18 October, 2013
Treatment: Method of treating pulmonary arterial hypertension by administering a pharmaceutical composition comprising macitentan and a polysorbate, wherein the polysorbate represents 0.1 to 1% of the weight of ...
Dosage: TABLET
How can I launch a generic of OPSUMIT before it's drug patent expiration?
More Information on Dosage
OPSUMIT family patents
137. Opzelura patent expiration
OPZELURA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8722693 | INCYTE CORP | Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
Jun, 2028
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8822481 | INCYTE CORP | Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d] pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
Jun, 2028
(3 years from now) | |
| US10610530 | INCYTE CORP | Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
Jun, 2028
(3 years from now) | |
|
US7598257 (Pediatric) | INCYTE CORP | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors |
Jun, 2028
(3 years from now) | |
|
US8415362 (Pediatric) | INCYTE CORP | Pyrazolyl substituted pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors |
Jun, 2028
(3 years from now) | |
|
US8822481 (Pediatric) | INCYTE CORP | Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d] pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
Dec, 2028
(4 years from now) | |
|
US8722693 (Pediatric) | INCYTE CORP | Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
Dec, 2028
(4 years from now) | |
|
US10610530 (Pediatric) | INCYTE CORP | Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
Dec, 2028
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Sep 21, 2024 |
| New Indication(I-896) | Jul 18, 2025 |
| Pediatric Exclusivity(PED) | Jan 18, 2026 |
Drugs and Companies using RUXOLITINIB PHOSPHATE ingredient
Market Authorisation Date: 21 September, 2021
Treatment: For topical short-term, non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised patients whose disease is not adequately controlled with topical prescription th...
Dosage: CREAM
More Information on Dosage
OPZELURA family patents
138. Orenitram patent expiration
ORENITRAM IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9604901 | UNITED THERAP | Process to prepare treprostinil, the active ingredient in Remodulin® |
Dec, 2028
(4 years from now) | |
| US11723887 | UNITED THERAP | Process to prepare treprostinil, the active ingredient in Remodulin® |
Dec, 2028
(4 years from now) | |
| US8497393 | UNITED THERAP | Process to prepare treprostinil, the active ingredient in Remodulin® |
Dec, 2028
(4 years from now) | |
| US9593066 | UNITED THERAP | Process to prepare treprostinil, the active ingredient in remodulin® |
Dec, 2028
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Dec 20, 2016 |
| New Dosing Schedule(D-156) | Jan 28, 2019 |
| New Dosing Schedule(D-157) | Jan 28, 2019 |
| Orphan Drug Exclusivity(ODE-308) | Dec 20, 2020 |
| New Indication(I-820) | Oct 18, 2022 |
| Orphan Drug Exclusivity(ODE-272) | Oct 18, 2026 |
Drugs and Companies using TREPROSTINIL DIOLAMINE ingredient
Market Authorisation Date: 20 December, 2013
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE
How can I launch a generic of ORENITRAM before it's drug patent expiration?
More Information on Dosage
ORENITRAM family patents
139. Oriahnn (copackaged) patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11459305 | ABBVIE | Processes for the preparation of uracil derivatives |
Nov, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 29, 2023 |
| New Chemical Entity Exclusivity(NCE) | Jul 23, 2023 |
NCE-1 date: 23 July, 2022
Market Authorisation Date: 29 May, 2020
Treatment: Management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids)
Dosage: CAPSULE
How can I launch a generic of ORIAHNN (COPACKAGED) before it's drug patent expiration?
More Information on Dosage
ORIAHNN (COPACKAGED) family patents
140. Orkambi patent expiration
ORKAMBI's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10597384 | VERTEX PHARMS INC | Solid forms of 3-(6-(1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid |
Dec, 2028
(4 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9150552 | VERTEX PHARMS INC | Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid |
Dec, 2028
(4 years from now) | |
| US12065432 | VERTEX PHARMS INC | Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid |
Dec, 2028
(4 years from now) | |
| US11052075 | VERTEX PHARMS INC | Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid and administration thereof |
Dec, 2028
(4 years from now) | |
| US8653103 | VERTEX PHARMS INC | Solid forms of 3-(6-(1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid |
Dec, 2028
(4 years from now) | |
| US10076513 | VERTEX PHARMS INC | Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid and administration thereof |
Dec, 2028
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Sep 02, 2025 |
| Pediatric Exclusivity(PED) | Jan 02, 2023 |
| New Chemical Entity Exclusivity(NCE) | Jul 02, 2020 |
| M(M-218) | Jan 25, 2021 |
| New Product(NP) | Aug 07, 2021 |
| Orphan Drug Exclusivity(ODE-93) | Jul 02, 2022 |
| Orphan Drug Exclusivity(ODE) | Sep 28, 2023 |
| Orphan Drug Exclusivity(ODE-123) | Sep 28, 2023 |
| Orphan Drug Exclusivity(ODE-195) | Aug 07, 2025 |
| New Strength(NS) | Sep 02, 2025 |
| Generating Antibiotic Incentives Now(GAIN) | Jan 02, 2028 |
| Orphan Drug Exclusivity(ODE-408) | Sep 02, 2029 |
Drugs and Companies using IVACAFTOR; LUMACAFTOR ingredient
NCE-1 date: 02 January, 2022
Market Authorisation Date: 28 September, 2016
Treatment: Treatment of cystic fibrosis in a patient age 2-5 years who is homozygous for the f508del mutation in the cftr gene using lumacaftor form i and ivacaftor; Treatment of cystic fibrosis in patients aged...
Dosage: TABLET; GRANULE
More Information on Dosage
ORKAMBI family patents
141. Oseni patent expiration
Can you believe OSENI received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7807689 | TAKEDA PHARMS USA | Dipeptidyl peptidase inhibitors |
Jun, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Jan 25, 2016 |
| New Chemical Entity Exclusivity(NCE) | Jan 25, 2018 |
| M(M-177) | Apr 05, 2019 |
Drugs and Companies using ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE ingredient
NCE-1 date: 25 January, 2017
Market Authorisation Date: 25 January, 2013
Treatment: Method of treating diabetes comprising administering alogliptin
Dosage: TABLET
More Information on Dosage
OSENI family patents
142. Osmolex Er patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8389578 | SUPERNUS PHARMS | Composition and method for treating neurological disease |
Jan, 2028
(3 years from now) | |
Drugs and Companies using AMANTADINE HYDROCHLORIDE ingredient
Market Authorisation Date: 16 February, 2018
Treatment: Treatment of parkinson's disease
Dosage: TABLET, EXTENDED RELEASE
More Information on Dosage
OSMOLEX ER family patents
143. Osmoprep patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7687075 | SALIX PHARMS | Colonic purgative composition with soluble binding agent |
Jun, 2028
(3 years from now) | |
Market Authorisation Date: 16 March, 2006
Treatment: NA
Dosage: TABLET
How can I launch a generic of OSMOPREP before it's drug patent expiration?
More Information on Dosage
OSMOPREP family patents
144. Osphena patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8642079 | DUCHESNAY | Solid formulations of ospemifene |
Jul, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 26, 2018 |
| New Indication(I-793) | Jan 25, 2022 |
Drugs and Companies using OSPEMIFENE ingredient
NCE-1 date: 26 February, 2017
Market Authorisation Date: 26 February, 2013
Treatment: NA
Dosage: TABLET
How can I launch a generic of OSPHENA before it's drug patent expiration?
More Information on Dosage
OSPHENA family patents
145. Otezla patent expiration
OTEZLA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7427638 | AMGEN INC | (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione:, and methods of synthesis and compositions thereof |
Feb, 2028
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7427638 (Pediatric) | AMGEN INC | (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione:, and methods of synthesis and compositions thereof |
Aug, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-694) | Sep 23, 2017 |
| New Chemical Entity Exclusivity(NCE) | Mar 21, 2019 |
| New Indication(I-803) | Jul 19, 2022 |
| M(M-257) | Apr 10, 2023 |
| New Indication(I-884) | Dec 20, 2024 |
| Orphan Drug Exclusivity(ODE-248) | Jul 19, 2026 |
| M(M-299) | Jul 20, 2026 |
| Pediatric Exclusivity(PED) | Jan 20, 2027 |
| New Patient Population(NPP) | Apr 25, 2027 |
Drugs and Companies using APREMILAST ingredient
NCE-1 date: 20 January, 2026
Market Authorisation Date: 21 March, 2014
Treatment: NA
Dosage: TABLET
How can I launch a generic of OTEZLA before it's drug patent expiration?
More Information on Dosage
OTEZLA family patents
146. Oxlumo patent expiration
Can you believe OXLUMO received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10131907 | ALNYLAM PHARMS INC | Glycoconjugates of RNA interference agents |
Aug, 2028
(3 years from now) | |
| US8828956 | ALNYLAM PHARMS INC | Carbohydrate conjugates as delivery agents for oligonucleotides |
Dec, 2028
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-901) | Oct 06, 2025 |
| New Chemical Entity Exclusivity(NCE) | Nov 23, 2025 |
| Orphan Drug Exclusivity(ODE-339) | Nov 23, 2027 |
| Orphan Drug Exclusivity(ODE-415) | Oct 06, 2029 |
Drugs and Companies using LUMASIRAN SODIUM ingredient
NCE-1 date: 23 November, 2024
Market Authorisation Date: 23 November, 2020
Treatment: Treatment of primary hyperoxaluria type 1 (ph1)
Dosage: SOLUTION
More Information on Dosage
OXLUMO family patents
147. Pancreaze patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8562978 | VIVUS INC | Stable digestive enzyme compositions |
Feb, 2028
(3 years from now) | |
| US8562981 | VIVUS INC | Stable digestive enzyme compositions |
Feb, 2028
(3 years from now) | |
| US8562980 | VIVUS INC | Stable digestive enzyme compositions |
Feb, 2028
(3 years from now) | |
| US8562979 | VIVUS INC | Stable digestive enzyme compositions |
Feb, 2028
(3 years from now) | |
| US8221747 | VIVUS INC | Stable pancreatic enzyme compositions |
Feb, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 12, 2015 |
Drugs and Companies using PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) ingredient
NCE-1 date: 12 April, 2014
Market Authorisation Date: 07 March, 2014
Treatment: Treatment of exocrine pancreatic insufficiency due to cystic fibrosis or other conditions
Dosage: CAPSULE, DELAYED RELEASE
More Information on Dosage
PANCREAZE family patents
148. Pennsaid patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8252838 | HORIZON | Diclofenac topical formulation |
Apr, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Nov 04, 2012 |
| New Product(NP) | Jan 16, 2017 |
Drugs and Companies using DICLOFENAC SODIUM ingredient
Market Authorisation Date: 16 January, 2014
Treatment: Use of topical diclofenac on a joint for treating osteoarthritis
Dosage: SOLUTION
How can I launch a generic of PENNSAID before it's drug patent expiration?
More Information on Dosage
PENNSAID family patents
149. Perseris Kit patent expiration
PERSERIS KIT's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9180197 | INDIVIOR | Sustained delivery formulations of risperidone compounds |
Feb, 2028
(3 years from now) | |
| US11013809 | INDIVIOR | Sustained delivery formulations of risperidone compound |
Feb, 2028
(3 years from now) | |
| US9186413 | INDIVIOR | Sustained delivery formulations of risperidone compounds |
Feb, 2028
(3 years from now) | |
| US10010612 | INDIVIOR | Sustained delivery formulations of risperidone compounds |
Feb, 2028
(3 years from now) | |
| US10376590 | INDIVIOR | Sustained delivery formulations of risperidone compound |
Feb, 2028
(3 years from now) | |
| US11712475 | INDIVIOR | Sustained delivery formulations of risperidone compound |
Feb, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jul 27, 2021 |
Drugs and Companies using RISPERIDONE ingredient
Market Authorisation Date: 27 July, 2018
Treatment: Treating schizophrenia; Treatment of schizophrenia; Method of treating schizophrenia
Dosage: FOR SUSPENSION, EXTENDED RELEASE
More Information on Dosage
PERSERIS KIT family patents
150. Pluvicto patent expiration
PLUVICTO's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11318121 | NOVARTIS | PSMA binding ligand-linker conjugates and methods for using |
Aug, 2028
(3 years from now) | |
| US10406240 | NOVARTIS | PSMA binding ligand-linker conjugates and methods for using |
Aug, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 23, 2027 |
Drugs and Companies using LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN ingredient
NCE-1 date: 23 March, 2026
Market Authorisation Date: 23 March, 2022
Treatment: For treatment of adult patients with prostate-specific membrane antigen (psma)-positive metastatic castration-resistant prostate cancer (mcrpc) who have been treated with androgen receptor (ar) pathwa...
Dosage: SOLUTION
More Information on Dosage
PLUVICTO family patents
151. Pradaxa patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7866474 (Pediatric) | BOEHRINGER INGELHEIM | Film container |
Mar, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 19, 2015 |
| New Indication(I-682) | Apr 04, 2017 |
| New Indication(I-683) | Apr 04, 2017 |
| M(M-168) | Nov 20, 2018 |
| New Strength(NS) | Nov 20, 2018 |
| New Indication(I-862) | Jun 21, 2024 |
| New Product(NP) | Jun 21, 2024 |
| Pediatric Exclusivity(PED) | Dec 21, 2024 |
Drugs and Companies using DABIGATRAN ETEXILATE MESYLATE ingredient
NCE-1 date: 22 December, 2023
Market Authorisation Date: 19 October, 2010
Treatment: NA
Dosage: CAPSULE
How can I launch a generic of PRADAXA before it's drug patent expiration?
More Information on Dosage
PRADAXA family patents
152. Prepopik patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8450338 | FERRING PHARMS INC | Granular compositions of sodium picosulphate and potassium bicarbonate and uses thereof |
Oct, 2028
(3 years from now) | |
| US8481083 | FERRING PHARMS INC | Granular compositions of magnesium oxide and citric acid and uses thereof |
Oct, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jul 16, 2015 |
| New Patient Population(NPP) | Aug 15, 2021 |
Drugs and Companies using CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE ingredient
Market Authorisation Date: 16 July, 2012
Treatment: NA
Dosage: FOR SOLUTION
How can I launch a generic of PREPOPIK before it's drug patent expiration?
More Information on Dosage
PREPOPIK family patents
153. Proair Digihaler patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8651103 | TEVA BRANDED PHARM | Dry powder inhalation apparatus |
Mar, 2028
(3 years from now) | |
Drugs and Companies using ALBUTEROL SULFATE ingredient
Market Authorisation Date: 21 December, 2018
Treatment: NA
Dosage: POWDER, METERED
More Information on Dosage
PROAIR DIGIHALER family patents
154. Proair Hfa patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8132712 | TEVA BRANDED PHARM | Metered-dose inhaler |
Sep, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Sep 16, 2011 |
Drugs and Companies using ALBUTEROL SULFATE ingredient
Market Authorisation Date: 29 October, 2004
Treatment: NA
Dosage: AEROSOL, METERED
How can I launch a generic of PROAIR HFA before it's drug patent expiration?
More Information on Dosage
PROAIR HFA family patents
155. Proair Respiclick patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8651103 | TEVA BRANDED PHARM | Dry powder inhalation apparatus |
Mar, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 12, 2018 |
| New Patient Population(NPP) | Apr 28, 2019 |
Drugs and Companies using ALBUTEROL SULFATE ingredient
Market Authorisation Date: 21 December, 2018
Treatment: NA
Dosage: POWDER, METERED
More Information on Dosage
PROAIR RESPICLICK family patents
156. Procysbi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8026284 (Pediatric) | HORIZON | Enterically coated cystamine, cysteamine and derivatives thereof |
Mar, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Apr 30, 2016 |
| New Patient Population(NPP) | Aug 14, 2018 |
| Orphan Drug Exclusivity(ODE-45) | Apr 30, 2020 |
| M(M-216) | Dec 22, 2020 |
| Orphan Drug Exclusivity(ODE) | Aug 14, 2022 |
| Orphan Drug Exclusivity(ODE-97) | Aug 14, 2022 |
| ODE*(ODE*) | Dec 22, 2024 |
| Orphan Drug Exclusivity(ODE-162) | Dec 22, 2024 |
| Pediatric Exclusivity(PED) | Jun 22, 2025 |
Drugs and Companies using CYSTEAMINE BITARTRATE ingredient
Market Authorisation Date: 14 February, 2020
Treatment: NA
Dosage: GRANULE, DELAYED RELEASE; CAPSULE, DELAYED RELEASE
How can I launch a generic of PROCYSBI before it's drug patent expiration?
More Information on Dosage
PROCYSBI family patents
157. Promacta patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8052993 (Pediatric) | NOVARTIS | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
Feb, 2028
(3 years from now) | |
|
US8052995 (Pediatric) | NOVARTIS | 3'-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene] hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
Feb, 2028
(3 years from now) | |
|
US8062665 (Pediatric) | NOVARTIS | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1 ,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
Feb, 2028
(3 years from now) | |
|
US8071129 (Pediatric) | NOVARTIS | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
Feb, 2028
(3 years from now) | |
|
US8052994 (Pediatric) | NOVARTIS | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene] hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
Feb, 2028
(3 years from now) | |
|
US8828430 (Pediatric) | NOVARTIS | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
Feb, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 20, 2013 |
| New Indication(I-664) | Nov 16, 2015 |
| Orphan Drug Exclusivity(ODE) | Nov 20, 2015 |
| New Dosing Schedule(D-149) | Jun 11, 2018 |
| New Indication(I-711) | Jun 11, 2018 |
| Orphan Drug Exclusivity(ODE-75) | Aug 26, 2021 |
| Pediatric Exclusivity(PED) | Feb 26, 2022 |
| Orphan Drug Exclusivity(ODE-210) | Nov 16, 2025 |
Drugs and Companies using ELTROMBOPAG OLAMINE ingredient
NCE-1 date: 26 February, 2021
Market Authorisation Date: 20 October, 2011
Treatment: NA
Dosage: TABLET
How can I launch a generic of PROMACTA before it's drug patent expiration?
More Information on Dosage
PROMACTA family patents
158. Qbrexza patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10052267 | JOURNEY | Topical glycopyrrolate formulations |
Oct, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jun 28, 2021 |
Drugs and Companies using GLYCOPYRRONIUM TOSYLATE ingredient
Market Authorisation Date: 28 June, 2018
Treatment: Topical treatment of primary axillary hyperhidrosis in adults and pediatric patients 9 years of age and older
Dosage: CLOTH
How can I launch a generic of QBREXZA before it's drug patent expiration?
More Information on Dosage
QBREXZA family patents
159. Qsymia patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9011906 | VIVUS LLC | Escalating dosing regimen for effecting weight loss and treating obesity |
Jun, 2028
(3 years from now) | |
| US8895058 | VIVUS LLC | Low dose topiramate/phentermine composition and methods of use thereof |
Jun, 2028
(3 years from now) | |
| US8895057 | VIVUS LLC | Escalating dosing regimen for effecting weight loss and treating obesity |
Jun, 2028
(3 years from now) | |
| US9011905 | VIVUS LLC | Low dose topiramate/phentermine composition and methods of use thereof |
Jun, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Jul 17, 2015 |
| New Patient Population(NPP) | Jun 24, 2025 |
Drugs and Companies using PHENTERMINE HYDROCHLORIDE; TOPIRAMATE ingredient
Market Authorisation Date: 17 July, 2012
Treatment: For chronic weight management in adults with bmi >=30 kg/m2 or bmi >=27 kg/m2 with a weight-related comorbidity, and patients age 12-17 with bmi >=25 kg/m2 in the 95th percentile or greater (standardi...
Dosage: CAPSULE, EXTENDED RELEASE
How can I launch a generic of QSYMIA before it's drug patent expiration?
More Information on Dosage
QSYMIA family patents
160. Qtern patent expiration
QTERN's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8716251 | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Mar, 2028
(3 years from now) | |
| US8361972 | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Mar, 2028
(3 years from now) | |
| US8221786 | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Mar, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 08, 2019 |
| M(M-175) | Apr 05, 2019 |
| New Combination(NC) | Feb 27, 2020 |
| New Indication(I-804) | May 02, 2022 |
| New Strength(NS) | May 02, 2022 |
Drugs and Companies using DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE ingredient
NCE-1 date: 08 January, 2018
Market Authorisation Date: 02 May, 2019
Treatment: Treatment of type 2 diabetes mellitus
Dosage: TABLET
How can I launch a generic of QTERN before it's drug patent expiration?
More Information on Dosage
QTERN family patents
161. Qternmet Xr patent expiration
QTERNMET XR's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8716251 | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Mar, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 02, 2022 |
Market Authorisation Date: 02 May, 2019
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE
More Information on Dosage
QTERNMET XR family patents
162. Qutenza patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9226903 | AVERITAS | Transdermal therapeutic system comprising an adhesive layer method for siliconizing the back layer or the system and use of said back layer |
Dec, 2028
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 16, 2014 |
| Orphan Drug Exclusivity(ODE) | Nov 16, 2016 |
| New Indication(I-838) | Jul 17, 2023 |
Drugs and Companies using CAPSAICIN ingredient
NCE-1 date: 16 November, 2013
Market Authorisation Date: 16 November, 2009
Treatment: NA
Dosage: PATCH
More Information on Dosage
QUTENZA family patents
163. Qvar Redihaler patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8132712 | NORTON WATERFORD | Metered-dose inhaler |
Sep, 2028
(3 years from now) | |
Drugs and Companies using BECLOMETHASONE DIPROPIONATE ingredient
Market Authorisation Date: 03 August, 2017
Treatment: NA
Dosage: AEROSOL, METERED
More Information on Dosage
QVAR REDIHALER family patents
164. Rayaldee patent expiration
RAYALDEE's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8207149 | EIRGEN | Method for treating secondary hyperparathyroidism in CKD |
Apr, 2028
(3 years from now) | |
| US9408858 | EIRGEN | Method for treating secondary hyperparathyroidism in CKD |
Apr, 2028
(3 years from now) | |
| US11154509 | EIRGEN | Methods for controlled release oral dosage of a vitamin D compound |
Apr, 2028
(3 years from now) | |
| US8778373 | EIRGEN | Methods for controlled release oral dosage of a vitamin D compound |
Apr, 2028
(3 years from now) | |
| US9498486 | EIRGEN | Method for controlled release oral dosage of a vitamin D compound |
Apr, 2028
(3 years from now) | |
| US9925147 | EIRGEN | Method for treating secondary hyperparathyroidism in CKD |
Apr, 2028
(3 years from now) | |
| US8361488 | EIRGEN | Methods and compositions for controlled release oral dosage of a vitamin D compound |
Jul, 2028
(3 years from now) | |
| US8426391 | EIRGEN | Treating vitamin D insufficiency and deficiency with 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 |
Aug, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jun 17, 2019 |
Drugs and Companies using CALCIFEDIOL ingredient
Market Authorisation Date: 17 June, 2016
Treatment: Treatment of secondary hyperparathyroidism in patients with stage 3 or 4 chronic kidney disease using controlled release, oral 25-hydroxyvitamin d; Use of controlled release 25-hydroxyvitamin d in tre...
Dosage: CAPSULE, EXTENDED RELEASE
More Information on Dosage
RAYALDEE family patents
165. Rayos patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8168218 | HORIZON | Delayed release tablet with defined core geometry |
Jan, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-128) | Jul 26, 2015 |
Drugs and Companies using PREDNISONE ingredient
Market Authorisation Date: 26 July, 2012
Treatment: Treatment of rheumatologic, allergic, pulmonary, gastrointestinal, dermatologic diseases or conditions by the use of a delayed release 5mg prednisone tablet
Dosage: TABLET, DELAYED RELEASE
How can I launch a generic of RAYOS before it's drug patent expiration?
More Information on Dosage
RAYOS family patents
166. Reclast patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7932241 | SANDOZ | Pharmaceutical products comprising bisphosphonates |
Feb, 2028
(3 years from now) | |
|
US7932241 (Pediatric) | SANDOZ | Pharmaceutical products comprising bisphosphonates |
Aug, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-581) | Dec 19, 2011 |
| New Indication(I-584) | Mar 15, 2012 |
| New Indication(I-595) | May 29, 2012 |
Drugs and Companies using ZOLEDRONIC ACID ingredient
Market Authorisation Date: 16 April, 2007
Treatment: NA
Dosage: INJECTABLE
How can I launch a generic of RECLAST before it's drug patent expiration?
More Information on Dosage
RECLAST family patents
167. Remodulin patent expiration
REMODULIN's oppositions filed in EPO
REMODULIN IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9593066 | UNITED THERAP | Process to prepare treprostinil, the active ingredient in remodulin® |
Dec, 2028
(4 years from now) | |
| US11723887 | UNITED THERAP | Process to prepare treprostinil, the active ingredient in Remodulin® |
Dec, 2028
(4 years from now) | |
| US9604901 | UNITED THERAP | Process to prepare treprostinil, the active ingredient in Remodulin® |
Dec, 2028
(4 years from now) | |
| US8497393 | UNITED THERAP | Process to prepare treprostinil, the active ingredient in Remodulin® |
Dec, 2028
(4 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8653137 | UNITED THERAP | Buffer solutions having selective bactericidal activity against gram negative bacteria and methods of using same |
Sep, 2028
(3 years from now) | |
| US8658694 | UNITED THERAP | Buffer solutions having selective bactericidal activity against gram negative bacteria and methods of using same |
Sep, 2028
(3 years from now) | |
Drugs and Companies using TREPROSTINIL ingredient
Market Authorisation Date: 28 September, 2023
Treatment: Administration of remodulin diluted for intravenous infusion with sterile diluent for flolan or sterile diluent for epoprostenol sodium prior to administration
Dosage: INJECTABLE; SOLUTION
How can I launch a generic of REMODULIN before it's drug patent expiration?
More Information on Dosage
REMODULIN family patents
168. Revlimid patent expiration
REVLIMID IPR and PTAB Proceedings
Can you believe REVLIMID received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8741929 | BRISTOL MYERS SQUIBB | Methods using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of mantle cell lymphomas |
Mar, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | Jun 05, 2020 |
| New Indication(I-672) | Jun 05, 2016 |
| New Strength(NS) | Jun 05, 2016 |
| New Indication(I-706) | Feb 17, 2018 |
| Orphan Drug Exclusivity(ODE-49) | Jun 05, 2020 |
| Orphan Drug Exclusivity(ODE-88) | Feb 17, 2022 |
| New Indication(I-796) | May 28, 2022 |
| New Indication(I-797) | May 28, 2022 |
| Orphan Drug Exclusivity(ODE-131) | Feb 22, 2024 |
| Orphan Drug Exclusivity(ODE-241) | May 28, 2026 |
| Orphan Drug Exclusivity(ODE-245) | May 28, 2026 |
Drugs and Companies using LENALIDOMIDE ingredient
Market Authorisation Date: 21 December, 2011
Treatment: Use of revlimid (lenalidomide) for the treatment of patients with mantle cell lymphoma whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib
Dosage: CAPSULE
How can I launch a generic of REVLIMID before it's drug patent expiration?
More Information on Dosage
REVLIMID family patents
169. Rexulti patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE48059 | OTSUKA | Piperazine-substituted benzothiophenes for treatment of mental disorders |
Dec, 2028
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-186) | Sep 23, 2019 |
| New Chemical Entity Exclusivity(NCE) | Jul 10, 2020 |
| New Patient Population(NPP) | Dec 27, 2024 |
| New Indication(I-913) | May 10, 2026 |
| Pediatric Exclusivity(PED) | Nov 10, 2026 |
| M(M-14) | May 08, 2027 |
Drugs and Companies using BREXPIPRAZOLE ingredient
NCE-1 date: 10 November, 2025
Market Authorisation Date: 10 July, 2015
Treatment: NA
Dosage: TABLET
How can I launch a generic of REXULTI before it's drug patent expiration?
More Information on Dosage
REXULTI family patents
170. Reyvow patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7423050 | ELI LILLY AND CO | Pyridinoylpiperidines as 5-HT1F agonists |
Feb, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 31, 2025 |
Drugs and Companies using LASMIDITAN SUCCINATE ingredient
NCE-1 date: 01 February, 2024
Market Authorisation Date: 31 January, 2020
Treatment: Acute treatment of migraine
Dosage: TABLET
More Information on Dosage
REYVOW family patents
171. Rhofade patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7812049 | MAYNE PHARMA | Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists |
May, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jan 18, 2020 |
Drugs and Companies using OXYMETAZOLINE HYDROCHLORIDE ingredient
Market Authorisation Date: 18 January, 2017
Treatment: Topical treatment of persistent facial erythema associated with rosacea in adults with 1% oxymetazoline hydrochloride cream
Dosage: CREAM
How can I launch a generic of RHOFADE before it's drug patent expiration?
More Information on Dosage
RHOFADE family patents
172. Roxybond patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7955619 | PROTEGA PHARMS | Abuse resistant drugs, method of use and method of making |
Aug, 2028
(3 years from now) | |
| US10314788 | PROTEGA PHARMS | Pharmaceutical compositions configured to deter dosage form splitting |
Aug, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Apr 20, 2020 |
Drugs and Companies using OXYCODONE HYDROCHLORIDE ingredient
Market Authorisation Date: 20 April, 2017
Treatment: NA
Dosage: TABLET
More Information on Dosage
ROXYBOND family patents
173. Rozlytrek patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9029356 | GENENTECH INC | Substituted indazole derivatives active as kinase inhibitors |
Jul, 2028
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8673893 | GENENTECH INC | Substituted indazole derivatives active as kinase inhibitors |
Jul, 2028
(3 years from now) | |
| US9255087 | GENENTECH INC | Substituted indazole derivatives active as kinase inhibitors |
Jul, 2028
(3 years from now) | |
| US9616059 | GENENTECH INC | Substituted indazole derivatives active as kinase inhibitors |
Jul, 2028
(3 years from now) | |
| US9085558 | GENENTECH INC | Substituted indazole derivatives active as kinase inhibitors |
Jul, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 15, 2024 |
| Orphan Drug Exclusivity(ODE-265) | Aug 15, 2026 |
| Orphan Drug Exclusivity(ODE-313) | Aug 15, 2026 |
| New Product(NP) | Oct 20, 2026 |
| New Patient Population(NPP) | Oct 20, 2026 |
| Orphan Drug Exclusivity(ODE-448) | Oct 20, 2030 |
Drugs and Companies using ENTRECTINIB ingredient
NCE-1 date: 16 August, 2023
Market Authorisation Date: 15 August, 2019
Treatment: Treatment of ros1-positive non-small cell lung cancer; Treatment of solid tumors that have a neurotrophic tyrosine receptor kinase (ntrk) gene fusion
Dosage: CAPSULE
More Information on Dosage
ROZLYTREK family patents
174. Rydapt patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7973031 | NOVARTIS | Staurosporine derivatives as inhibitors of FLT3 receptor tyrosine kinase activity |
Oct, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 28, 2022 |
| Orphan Drug Exclusivity(ODE) | Apr 28, 2024 |
| Orphan Drug Exclusivity(ODE-140) | Apr 28, 2024 |
| Orphan Drug Exclusivity(ODE-141) | Apr 28, 2024 |
Drugs and Companies using MIDOSTAURIN ingredient
NCE-1 date: 28 April, 2021
Market Authorisation Date: 28 April, 2017
Treatment: Treatment of adult patients with newly diagnosed acute myeloid leukemia (aml) who are flt3 mutation-positive, in combination with standard cytarabine and daunorubicin induction and cytarabine consolid...
Dosage: CAPSULE
How can I launch a generic of RYDAPT before it's drug patent expiration?
More Information on Dosage
RYDAPT family patents
175. Rytary patent expiration
RYTARY's oppositions filed in EPO
Can you believe RYTARY received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8377474 | IMPAX | Controlled release formulations of levodopa and uses thereof |
Dec, 2028
(4 years from now) | |
| US9089607 | IMPAX | Controlled release formulations of levodopa and uses thereof |
Dec, 2028
(4 years from now) | |
| US8557283 | IMPAX | Controlled release formulations of levodopa and uses thereof |
Dec, 2028
(4 years from now) | |
| US9463246 | IMPAX | Controlled release formulations of levodopa and uses thereof |
Dec, 2028
(4 years from now) | |
| US9901640 | IMPAX | Controlled release formulations of levodopa and uses thereof |
Dec, 2028
(4 years from now) | |
| US9533046 | IMPAX | Controlled release formulations of levodopa and uses thereof |
Dec, 2028
(4 years from now) | |
| US9089608 | IMPAX | Controlled release formulations of levodopa and uses thereof |
Dec, 2028
(4 years from now) | |
| US8454998 | IMPAX | Controlled release formulations of levodopa and uses thereof |
Dec, 2028
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Jan 07, 2018 |
Drugs and Companies using CARBIDOPA; LEVODOPA ingredient
Market Authorisation Date: 07 January, 2015
Treatment: Treatment of parkinson's disease; Method of providing a therapeutically effective and stable median blood plasma level of levodopa; Treatment of parkinsonism that may follow carbon monoxide intoxicati...
Dosage: CAPSULE, EXTENDED RELEASE
How can I launch a generic of RYTARY before it's drug patent expiration?
More Information on Dosage
RYTARY family patents
176. Savaysa patent expiration
SAVAYSA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9149532 | DAIICHI SANKYO INC | Pharmaceutical composition |
Mar, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 08, 2020 |
| M(M-243) | Aug 09, 2022 |
| M(M-14) | Oct 18, 2026 |
Drugs and Companies using EDOXABAN TOSYLATE ingredient
NCE-1 date: 08 January, 2019
Market Authorisation Date: 08 January, 2015
Treatment: NA
Dosage: TABLET
How can I launch a generic of SAVAYSA before it's drug patent expiration?
More Information on Dosage
SAVAYSA family patents
177. Saxenda patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US9457154 (Pediatric) | NOVO | Injection device with an end of dose feedback mechanism |
Mar, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 25, 2015 |
| New Product(NP) | Jan 25, 2017 |
| New Patient Population(NPP) | Dec 04, 2023 |
Drugs and Companies using LIRAGLUTIDE ingredient
NCE-1 date: 25 January, 2014
Market Authorisation Date: 23 December, 2014
Treatment: NA
Dosage: SOLUTION
How can I launch a generic of SAXENDA before it's drug patent expiration?
More Information on Dosage
SAXENDA family patents
178. Seasonique patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7855190 | TEVA BRANDED PHARM | Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration |
Dec, 2028
(4 years from now) | |
Drugs and Companies using ETHINYL ESTRADIOL; LEVONORGESTREL ingredient
Market Authorisation Date: 25 May, 2006
Treatment: Prevention of pregnancy
Dosage: TABLET
How can I launch a generic of SEASONIQUE before it's drug patent expiration?
More Information on Dosage
SEASONIQUE family patents
179. Seebri patent expiration
SEEBRI's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8479730 | NOVARTIS | Inhaler device |
Oct, 2028
(3 years from now) | |
| US8182838 | NOVARTIS | Dry powder composition comprising co-jet milled particles for pulmonary inhalation |
Oct, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 29, 2018 |
Drugs and Companies using GLYCOPYRROLATE ingredient
Market Authorisation Date: 29 October, 2015
Treatment: NA
Dosage: POWDER
More Information on Dosage
SEEBRI family patents
180. Seysara patent expiration
Can you believe SEYSARA received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9481639 | ALMIRALL | Substituted tetracycline compounds for treatment of inflammatory skin disorders |
Aug, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 01, 2023 |
Drugs and Companies using SARECYCLINE HYDROCHLORIDE ingredient
NCE-1 date: 01 October, 2022
Market Authorisation Date: 01 October, 2018
Treatment: A method for treating acne in inflammatory lesions of non-nodular moderate to severe acne vulgaris patients 9 years of age and older comprising administering sarecycline hydrochloride in 60 mg, 100 mg...
Dosage: TABLET
More Information on Dosage
SEYSARA family patents
181. Signifor Lar Kit patent expiration
Can you believe SIGNIFOR LAR KIT received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9351923 | RECORDATI RARE | Extended-release composition comprising a somatostatin derivative in microparticles |
May, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 14, 2017 |
| New Product(NP) | Dec 15, 2017 |
| New Indication(I-785) | Jun 29, 2021 |
| Orphan Drug Exclusivity(ODE) | Dec 15, 2021 |
| Orphan Drug Exclusivity(ODE-81) | Dec 15, 2021 |
| Orphan Drug Exclusivity(ODE-268) | Jun 29, 2025 |
Drugs and Companies using PASIREOTIDE PAMOATE ingredient
NCE-1 date: 14 December, 2016
Market Authorisation Date: 29 June, 2018
Treatment: NA
Dosage: FOR SUSPENSION
More Information on Dosage
SIGNIFOR LAR KIT family patents
182. Silenor patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11234954 | CURRAX | Low-dose doxepin for treatment of sleep disorders in elderly patients |
Jan, 2028
(3 years from now) | |
| US10548871 | CURRAX | Low-dose doxepin formulations and methods of making and using the same |
Apr, 2028
(3 years from now) | |
| US9907780 | CURRAX | Low-dose doxepin formulations and methods of making and using the same |
Apr, 2028
(3 years from now) | |
| US11096920 | CURRAX | Low-dose doxepin formulations and methods of making and using the same |
Apr, 2028
(3 years from now) | |
| US9107898 | CURRAX | Methods of using low-dose doxepin for the improvement of sleep |
May, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 17, 2013 |
Drugs and Companies using DOXEPIN HYDROCHLORIDE ingredient
Market Authorisation Date: 17 March, 2010
Treatment: Treatment of insomnia
Dosage: TABLET
How can I launch a generic of SILENOR before it's drug patent expiration?
More Information on Dosage
SILENOR family patents
183. Sivextro patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8420676 | CUBIST PHARMS LLC | Oxazolidinone derivatives |
Feb, 2028
(3 years from now) | |
| US7816379 | CUBIST PHARMS LLC | Oxazolidinone derivatives |
Jun, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 20, 2019 |
| New Patient Population(NPP) | Jun 19, 2023 |
| Generating Antibiotic Incentives Now(GAIN) | Jun 20, 2024 |
Drugs and Companies using TEDIZOLID PHOSPHATE ingredient
NCE-1 date: 21 June, 2023
Market Authorisation Date: 20 June, 2014
Treatment: Method of treating bacterial infections; Method of treating acute bacterial skin and skin structure infections (absssi) caused by designated susceptible bacteria
Dosage: TABLET; POWDER
More Information on Dosage
SIVEXTRO family patents
184. Sorilux patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8263580 | MAYNE PHARMA | Vitamin formulation |
May, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Oct 06, 2013 |
| New Indication(I-657) | Sep 27, 2015 |
| New Patient Population(NPP) | Nov 05, 2022 |
Drugs and Companies using CALCIPOTRIENE ingredient
Market Authorisation Date: 06 October, 2010
Treatment: Use of calcipotriene foam for the topical treatment of plaque psoriasis in patients aged 4 years and older
Dosage: AEROSOL, FOAM
More Information on Dosage
SORILUX family patents
185. Sovaldi patent expiration
SOVALDI's oppositions filed in EPO
SOVALDI IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8580765 | GILEAD SCIENCES INC | NA |
Mar, 2028
(3 years from now) | |
| US8334270 | GILEAD SCIENCES INC | NA |
Mar, 2028
(3 years from now) | |
| US9085573 | GILEAD SCIENCES INC | NA |
Mar, 2028
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8334270 (Pediatric) | GILEAD SCIENCES INC | NA |
Sep, 2028
(3 years from now) | |
|
US8580765 (Pediatric) | GILEAD SCIENCES INC | NA |
Sep, 2028
(3 years from now) | |
|
US9085573 (Pediatric) | GILEAD SCIENCES INC | NA |
Sep, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 06, 2018 |
| New Patient Population(NPP) | Apr 07, 2020 |
| Orphan Drug Exclusivity(ODE) | Apr 07, 2024 |
| ODE*(ODE*) | Aug 28, 2026 |
| Orphan Drug Exclusivity(ODE-135) | Apr 07, 2024 |
| Pediatric Exclusivity(PED) | Oct 07, 2024 |
| Orphan Drug Exclusivity(ODE-258) | Aug 28, 2026 |
Drugs and Companies using SOFOSBUVIR ingredient
NCE-1 date: 08 October, 2023
Market Authorisation Date: 28 August, 2019
Treatment: For the treatment of hepatitis c
Dosage: TABLET; PELLETS
How can I launch a generic of SOVALDI before it's drug patent expiration?
More Information on Dosage
SOVALDI family patents
186. Spiriva Respimat patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7837235 | BOEHRINGER INGELHEIM | Device for clamping a fluidic component |
Mar, 2028
(3 years from now) | |
|
US7837235 (Pediatric) | BOEHRINGER INGELHEIM | Device for clamping a fluidic component |
Sep, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Sep 15, 2018 |
| New Patient Population(NPP) | Feb 15, 2020 |
| Pediatric Exclusivity(PED) | Aug 15, 2020 |
Drugs and Companies using TIOTROPIUM BROMIDE ingredient
Market Authorisation Date: 15 September, 2015
Treatment: NA
Dosage: SPRAY, METERED
How can I launch a generic of SPIRIVA RESPIMAT before it's drug patent expiration?
More Information on Dosage
SPIRIVA RESPIMAT family patents
187. Spy Agent Green Kit patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8185176 | NOVADAQ TECH | Method and apparatus for vasculature visualization with applications in neurosurgery and neurology |
Jun, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Nov 21, 2021 |
| New Indication(I-911) | Jun 05, 2026 |
Drugs and Companies using INDOCYANINE GREEN ingredient
Market Authorisation Date: 21 November, 2018
Treatment: Visualization of vessels, blood flow and tissue perfusion of vessel with arteriovenous malformation in vascular, gastrointestinal, organ transplant, and plastic, micro- and reconstructive, including ...
Dosage: POWDER
How can I launch a generic of SPY AGENT GREEN KIT before it's drug patent expiration?
More Information on Dosage
SPY AGENT GREEN KIT family patents
188. Staxyn patent expiration
STAXYN's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8613950 | BAYER HLTHCARE | Pharmaceutical forms with improved pharmacokinetic properties |
Dec, 2028
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Jun 17, 2013 |
Drugs and Companies using VARDENAFIL HYDROCHLORIDE ingredient
Market Authorisation Date: 17 June, 2010
Treatment: NA
Dosage: TABLET, ORALLY DISINTEGRATING
How can I launch a generic of STAXYN before it's drug patent expiration?
More Information on Dosage
STAXYN family patents
189. Stiolto Respimat patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7837235 | BOEHRINGER INGELHEIM | Device for clamping a fluidic component |
Mar, 2028
(3 years from now) | |
|
US7837235 (Pediatric) | BOEHRINGER INGELHEIM | Device for clamping a fluidic component |
Sep, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | May 21, 2018 |
| M(M-173) | Mar 18, 2019 |
| New Chemical Entity Exclusivity(NCE) | Jul 31, 2019 |
| M(M-233) | Oct 05, 2021 |
Drugs and Companies using OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE ingredient
NCE-1 date: 31 July, 2018
Market Authorisation Date: 21 May, 2015
Treatment: NA
Dosage: SPRAY, METERED
More Information on Dosage
STIOLTO RESPIMAT family patents
190. Striverdi Respimat patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7837235 | BOEHRINGER INGELHEIM | Device for clamping a fluidic component |
Mar, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 31, 2019 |
Drugs and Companies using OLODATEROL HYDROCHLORIDE ingredient
NCE-1 date: 31 July, 2018
Market Authorisation Date: 31 July, 2014
Treatment: NA
Dosage: SPRAY, METERED
More Information on Dosage
STRIVERDI RESPIMAT family patents
191. Suprax patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9233112 | LUPIN LTD | Pharmaceutical compositions of cefixime |
Dec, 2028
(4 years from now) | |
Drugs and Companies using CEFIXIME ingredient
Market Authorisation Date: 20 February, 2013
Treatment: Methods for treating bacterial infections
Dosage: FOR SUSPENSION
How can I launch a generic of SUPRAX before it's drug patent expiration?
More Information on Dosage
SUPRAX family patents
192. Symbicort patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8528545 | ASTRAZENECA | Inhaler device that reduces the risk for miscounting a dosage |
Oct, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-582) | Feb 27, 2012 |
| New Patient Population(NPP) | Jan 27, 2020 |
| Pediatric Exclusivity(PED) | Jul 27, 2020 |
| M(M-210) | Sep 11, 2020 |
| M(M-214) | Dec 20, 2020 |
Drugs and Companies using BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE ingredient
Market Authorisation Date: 21 July, 2006
Treatment: NA
Dosage: AEROSOL, METERED
How can I launch a generic of SYMBICORT before it's drug patent expiration?
More Information on Dosage
SYMBICORT family patents
193. Symproic patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8084460 | BDSI | 6,7-unsaturated-7-carbamoyl substituted morphinan derivative |
Jan, 2028
(3 years from now) | |
| USRE46365 | BDSI | 6,7-unsaturated-7-carbamoyl substituted morphinan derivative |
Jan, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 23, 2022 |
Drugs and Companies using NALDEMEDINE TOSYLATE ingredient
NCE-1 date: 23 March, 2021
Market Authorisation Date: 23 March, 2017
Treatment: NA
Dosage: TABLET
More Information on Dosage
SYMPROIC family patents
194. Syndros patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8222292 | BENUVIA OPERATIONS | Liquid cannabinoid formulations |
Aug, 2028
(3 years from now) | |
| US9345771 | BENUVIA OPERATIONS | Oral cannabinoid formulations |
Aug, 2028
(3 years from now) | |
| US10265293 | BENUVIA OPERATIONS | Oral cannabinoid formulations |
Aug, 2028
(3 years from now) | |
| US11253472 | BENUVIA OPERATIONS | Oral cannabinoid formulations |
Aug, 2028
(3 years from now) | |
Drugs and Companies using DRONABINOL ingredient
Market Authorisation Date: 23 March, 2017
Treatment: NA
Dosage: SOLUTION
How can I launch a generic of SYNDROS before it's drug patent expiration?
More Information on Dosage
SYNDROS family patents
195. Synjardy patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7579449 | BOEHRINGER INGELHEIM | Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture |
Aug, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Aug 26, 2018 |
| M(M-174) | Mar 18, 2019 |
| New Chemical Entity Exclusivity(NCE) | Aug 01, 2019 |
| New Indication(I-739) | Dec 02, 2019 |
| New Patient Population(NPP) | Jun 20, 2026 |
| Pediatric Exclusivity(PED) | Dec 20, 2026 |
Drugs and Companies using EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient
NCE-1 date: 20 December, 2025
Market Authorisation Date: 26 August, 2015
Treatment: NA
Dosage: TABLET
How can I launch a generic of SYNJARDY before it's drug patent expiration?
More Information on Dosage
SYNJARDY family patents
196. Synjardy Xr patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7579449 | BOEHRINGER INGELHEIM | Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture |
Aug, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 01, 2019 |
| New Indication(I-739) | Dec 02, 2019 |
| M(M-296) | Jun 20, 2026 |
| Pediatric Exclusivity(PED) | Dec 20, 2026 |
Drugs and Companies using EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient
NCE-1 date: 20 December, 2025
Market Authorisation Date: 09 December, 2016
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE
How can I launch a generic of SYNJARDY XR before it's drug patent expiration?
More Information on Dosage
SYNJARDY XR family patents
197. Tasigna patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8163904 | NOVARTIS | Salts of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-Benzamide |
Aug, 2028
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8293756 (Pediatric) | NOVARTIS | Pharmaceutical compositions comprising nilotinib hydrochloride monohydrate |
Mar, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 29, 2012 |
| New Indication(I-627) | Jun 17, 2014 |
| Orphan Drug Exclusivity(ODE) | Oct 29, 2014 |
| New Dosing Schedule(D-170) | Dec 22, 2020 |
| New Patient Population(NPP) | Mar 22, 2021 |
| Orphan Drug Exclusivity(ODE-171) | Mar 22, 2025 |
| Orphan Drug Exclusivity(ODE-172) | Mar 22, 2025 |
| Orphan Drug Exclusivity(ODE-380) | Sep 23, 2028 |
| Pediatric Exclusivity(PED) | Mar 23, 2029 |
Drugs and Companies using NILOTINIB HYDROCHLORIDE ingredient
NCE-1 date: 23 March, 2028
Market Authorisation Date: 22 March, 2018
Treatment: NA
Dosage: CAPSULE
How can I launch a generic of TASIGNA before it's drug patent expiration?
More Information on Dosage
TASIGNA family patents
198. Tavalisse patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8652492 | RIGEL PHARMS | Wet granulation using a water sequestering agent |
Nov, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 17, 2023 |
| Orphan Drug Exclusivity(ODE-174) | Apr 17, 2025 |
Drugs and Companies using FOSTAMATINIB DISODIUM ingredient
NCE-1 date: 17 April, 2022
Market Authorisation Date: 17 April, 2018
Treatment: NA
Dosage: TABLET
How can I launch a generic of TAVALISSE before it's drug patent expiration?
More Information on Dosage
TAVALISSE family patents
199. Tecfidera patent expiration
TECFIDERA's oppositions filed in EPO
TECFIDERA IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8399514 | BIOGEN INC | Treatment for multiple sclerosis |
Feb, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 27, 2018 |
| M(M-260) | Feb 05, 2023 |
Drugs and Companies using DIMETHYL FUMARATE ingredient
NCE-1 date: 27 March, 2017
Market Authorisation Date: 27 March, 2013
Treatment: Method of treating multiple sclerosis
Dosage: CAPSULE, DELAYED RELEASE
How can I launch a generic of TECFIDERA before it's drug patent expiration?
More Information on Dosage
TECFIDERA family patents
200. Tekturna Hct patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8618172 | NODEN PHARMA | Galenical formulations of organic compounds |
Jul, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 05, 2012 |
| New Indication(I-600) | Jul 16, 2012 |
Drugs and Companies using ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE ingredient
NCE-1 date: 06 March, 2011
Market Authorisation Date: 18 January, 2008
Treatment: NA
Dosage: TABLET
How can I launch a generic of TEKTURNA HCT before it's drug patent expiration?
More Information on Dosage
TEKTURNA HCT family patents
201. Tepmetko patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8921357 | EMD SERONO INC | Pyridazinone derivatives |
May, 2028
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9284300 | EMD SERONO INC | Pyridazinone derivatives |
Apr, 2028
(3 years from now) | |
| US9403799 | EMD SERONO INC | Pyrimidinyl-pyridazinone derivatives for treating a disease which is influenced by inhibition of met kinase |
Jul, 2028
(3 years from now) | |
| US8658643 | EMD SERONO INC | Pyrimidinyl pyridazinone derivatives |
Jul, 2028
(3 years from now) | |
| US9062029 | EMD SERONO INC | Pyrimidinyl pyridazinone derivatives |
Jul, 2028
(3 years from now) | |
| US8927540 | EMD SERONO INC | Pyridazinone derivatives |
Jul, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 03, 2026 |
| Orphan Drug Exclusivity(ODE-325) | Feb 03, 2028 |
Drugs and Companies using TEPOTINIB HYDROCHLORIDE ingredient
NCE-1 date: 03 February, 2025
Market Authorisation Date: 03 February, 2021
Treatment: Treating a solid tumor, including lung cancer, with a met alteration(s), or stabilizing or improving symptoms associated with having a solid tumor, including lung cancer, with a met alteration(s), by ...
Dosage: TABLET
More Information on Dosage
TEPMETKO family patents
202. Tivicay patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8129385 (Pediatric) | VIIV HLTHCARE | Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness |
Apr, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-166) | Jul 30, 2018 |
| New Chemical Entity Exclusivity(NCE) | Aug 12, 2018 |
| New Indication(I-758) | Nov 21, 2020 |
Drugs and Companies using DOLUTEGRAVIR SODIUM ingredient
NCE-1 date: 12 August, 2017
Market Authorisation Date: 09 June, 2016
Treatment: NA
Dosage: TABLET
How can I launch a generic of TIVICAY before it's drug patent expiration?
More Information on Dosage
TIVICAY family patents
203. Tivicay Pd patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8129385 (Pediatric) | VIIV HLTHCARE | Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness |
Apr, 2028
(3 years from now) | |
Drugs and Companies using DOLUTEGRAVIR SODIUM ingredient
Market Authorisation Date: 12 June, 2020
Treatment: NA
Dosage: TABLET, FOR SUSPENSION
How can I launch a generic of TIVICAY PD before it's drug patent expiration?
More Information on Dosage
TIVICAY PD family patents
204. Tobi Podhaler patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8869794 | MYLAN SPECIALITY LP | Aerosolization apparatus with capsule puncturing member |
Sep, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 22, 2016 |
Drugs and Companies using TOBRAMYCIN ingredient
Market Authorisation Date: 22 March, 2013
Treatment: Treatment of cystic fibrosis patients with pseudomonas aeruginosa
Dosage: POWDER
More Information on Dosage
TOBI PODHALER family patents
205. Tobradex St patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7795316 | HARROW EYE | Topical ophthalmic compositions containing tobramycin and dexamethasone |
Aug, 2028
(3 years from now) | |
Drugs and Companies using DEXAMETHASONE; TOBRAMYCIN ingredient
Market Authorisation Date: 13 February, 2009
Treatment: Use of a combination of tobramycin and dexamethasone to treat ocular inflammation where an infection or risk of infection exists
Dosage: SUSPENSION/DROPS
More Information on Dosage
TOBRADEX ST family patents
206. Topicort patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8277780 | TARO | Stable liquid desoximethasone compositions with reduced oxidized impurity |
Sep, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Apr 11, 2016 |
Drugs and Companies using DESOXIMETASONE ingredient
Market Authorisation Date: 11 April, 2013
Treatment: Treatment of plaque psoriasis in patients 18 years of age or older
Dosage: SPRAY
How can I launch a generic of TOPICORT before it's drug patent expiration?
More Information on Dosage
TOPICORT family patents
207. Toujeo Solostar patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7918833 (Pediatric) | SANOFI US SERVICES | Pen-type injector |
Mar, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Feb 25, 2018 |
| New Patient Population(NPP) | Nov 26, 2022 |
Drugs and Companies using INSULIN GLARGINE RECOMBINANT ingredient
Market Authorisation Date: 25 February, 2015
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
TOUJEO SOLOSTAR family patents
208. Trelegy Ellipta patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8161968 | GLAXOSMITHKLINE | Medicament dispenser |
Feb, 2028
(3 years from now) | |
|
US9333310 (Pediatric) | GLAXOSMITHKLINE | Medicament dispenser |
Apr, 2028
(3 years from now) | |
|
US8113199 (Pediatric) | GLAXOSMITHKLINE | Counter for use with a medicament dispenser |
Apr, 2028
(3 years from now) | |
|
US8161968 (Pediatric) | GLAXOSMITHKLINE | Medicament dispenser |
Aug, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 18, 2018 |
| New Indication(I-775) | Apr 24, 2021 |
| New Indication(I-843) | Sep 09, 2023 |
| New Strength(NS) | Sep 09, 2023 |
NCE-1 date: 18 December, 2017
Market Authorisation Date: 18 September, 2017
Treatment: NA
Dosage: POWDER
More Information on Dosage
TRELEGY ELLIPTA family patents
209. Trijardy Xr patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7579449 | BOEHRINGER INGELHEIM | Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture |
Aug, 2028
(3 years from now) | |
Drugs and Companies using EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE ingredient
Market Authorisation Date: 27 January, 2020
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE
How can I launch a generic of TRIJARDY XR before it's drug patent expiration?
More Information on Dosage
TRIJARDY XR family patents
210. Triumeq patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8129385 (Pediatric) | VIIV HLTHCARE | Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness |
Apr, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosing Schedule(D-147) | Mar 23, 2018 |
| New Chemical Entity Exclusivity(NCE) | Aug 12, 2018 |
| M(M-294) | Jun 15, 2026 |
| Pediatric Exclusivity(PED) | Dec 15, 2026 |
Drugs and Companies using ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE ingredient
NCE-1 date: 15 December, 2025
Market Authorisation Date: 22 August, 2014
Treatment: NA
Dosage: TABLET
How can I launch a generic of TRIUMEQ before it's drug patent expiration?
More Information on Dosage
TRIUMEQ family patents
211. Triumeq Pd patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8129385 (Pediatric) | VIIV HLTHCARE | Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness |
Apr, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Jun 15, 2026 |
| Pediatric Exclusivity(PED) | Dec 15, 2026 |
Drugs and Companies using ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE ingredient
Market Authorisation Date: 30 March, 2022
Treatment: NA
Dosage: TABLET, FOR SUSPENSION
How can I launch a generic of TRIUMEQ PD before it's drug patent expiration?
More Information on Dosage
TRIUMEQ PD family patents
212. Trokendi Xr patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8298576 | SUPERNUS PHARMS | Sustained-release formulations of topiramate |
Apr, 2028
(3 years from now) | |
Drugs and Companies using TOPIRAMATE ingredient
Market Authorisation Date: 16 August, 2013
Treatment: Use of trokendi xr for prophylactic treatment of migraine
Dosage: CAPSULE, EXTENDED RELEASE
How can I launch a generic of TROKENDI XR before it's drug patent expiration?
More Information on Dosage
TROKENDI XR family patents
213. Trulance patent expiration
TRULANCE's oppositions filed in EPO
TRULANCE IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7041786 | SALIX | Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis |
Jan, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-764) | Jan 24, 2021 |
| New Chemical Entity Exclusivity(NCE) | Jan 19, 2022 |
Drugs and Companies using PLECANATIDE ingredient
NCE-1 date: 19 January, 2021
Market Authorisation Date: 19 January, 2017
Treatment: NA
Dosage: TABLET
How can I launch a generic of TRULANCE before it's drug patent expiration?
More Information on Dosage
TRULANCE family patents
214. Truqap patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10059714 | ASTRAZENECA | Protein kinase B inhibitors |
Oct, 2028
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10654855 | ASTRAZENECA | Protein kinase B inhibitors |
Oct, 2028
(3 years from now) | |
| US11760760 | ASTRAZENECA | Protein kinase B inhibitors |
Oct, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 16, 2028 |
Drugs and Companies using CAPIVASERTIB ingredient
NCE-1 date: 17 November, 2027
Market Authorisation Date: 16 November, 2023
Treatment: Treatment with fulvestrant of hr-pos. her2-neg. locally advanced or metastatic breast cancer with pik3ca/akt1/pten-alteration(s) following progression on endocrine therapy in the metastatic setting or...
Dosage: TABLET
More Information on Dosage
TRUQAP family patents
215. Truseltiq patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9067896 | HELSINN HLTHCARE | Crystalline forms of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl) -phenylamino]-pyrimidin-4-yl}-1-methyl-urea and salts thereof |
Aug, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 28, 2026 |
| Orphan Drug Exclusivity(ODE-353) | May 28, 2028 |
Drugs and Companies using INFIGRATINIB PHOSPHATE ingredient
NCE-1 date: 28 May, 2025
Market Authorisation Date: 28 May, 2021
Treatment: NA
Dosage: CAPSULE
More Information on Dosage
TRUSELTIQ family patents
216. Turalio patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8461169 | DAIICHI SANKYO INC | Compounds modulating c-fms and/or c-kit activity |
Apr, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 02, 2024 |
| ODE*(ODE*) | Aug 02, 2026 |
| Orphan Drug Exclusivity(ODE-250) | Aug 02, 2026 |
Drugs and Companies using PEXIDARTINIB HYDROCHLORIDE ingredient
NCE-1 date: 03 August, 2023
Market Authorisation Date: 14 October, 2022
Treatment: Treatment of adult patients with symptomatic tenosynovial giant cell tumor (tgct) associated with severe morbidity or functional limitations and not amenable to improvement with surgery
Dosage: CAPSULE
More Information on Dosage
TURALIO family patents
217. Twirla patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9050348 | AGILE | Dermal delivery device |
Jul, 2028
(3 years from now) | |
| US8747888 | AGILE | Dermal delivery device with in situ seal |
Jul, 2028
(3 years from now) | |
| US8246978 | AGILE | Dermal delivery device with reduced loss of its volatile components |
Aug, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Feb 14, 2023 |
Drugs and Companies using ETHINYL ESTRADIOL; LEVONORGESTREL ingredient
Market Authorisation Date: 14 February, 2020
Treatment: NA
Dosage: SYSTEM
More Information on Dosage
TWIRLA family patents
218. Twyneo patent expiration
Can you believe TWYNEO received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8617580 | GALDERMA LABS LP | Compositions for topical application comprising a peroxide and retinoid |
Feb, 2028
(3 years from now) | |
| US9868103 | GALDERMA LABS LP | Metal oxide coating of water insoluble ingredients |
Aug, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Jul 26, 2024 |
Drugs and Companies using BENZOYL PEROXIDE; TRETINOIN ingredient
Market Authorisation Date: 26 July, 2021
Treatment: Topical treatment of acne vulgaris in adults and pediatric patients 9 years of age and older
Dosage: CREAM
More Information on Dosage
TWYNEO family patents
219. Tygacil patent expiration
TYGACIL's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8975242 | PF PRISM CV | Tigecycline compositions and methods of preparation |
Oct, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-586) | Mar 20, 2012 |
| New Indication(I-587) | Mar 20, 2012 |
| New Indication(I-588) | Mar 20, 2012 |
Drugs and Companies using TIGECYCLINE ingredient
Market Authorisation Date: 15 June, 2005
Treatment: NA
Dosage: POWDER
More Information on Dosage
TYGACIL family patents
220. Tyvaso patent expiration
TYVASO IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9604901 | UNITED THERAP | Process to prepare treprostinil, the active ingredient in Remodulin® |
Dec, 2028
(4 years from now) | |
| US9593066 | UNITED THERAP | Process to prepare treprostinil, the active ingredient in remodulin® |
Dec, 2028
(4 years from now) | |
| US11723887 | UNITED THERAP | Process to prepare treprostinil, the active ingredient in Remodulin® |
Dec, 2028
(4 years from now) | |
| US8497393 | UNITED THERAP | Process to prepare treprostinil, the active ingredient in Remodulin® |
Dec, 2028
(4 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9339507 | UNITED THERAP | Treprostinil administration by inhalation |
Mar, 2028
(3 years from now) | |
| US9358240 | UNITED THERAP | Treprostinil administration by inhalation |
May, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Jul 30, 2012 |
| Orphan Drug Exclusivity(ODE) | Jul 30, 2016 |
| M(M-145) | May 20, 2017 |
| New Indication(I-856) | Mar 31, 2024 |
Drugs and Companies using TREPROSTINIL ingredient
Market Authorisation Date: 30 July, 2009
Treatment: Method of treating pulmonary hypertension by administering treprostinil or a salt thereof by inhalation using a device
Dosage: SOLUTION
How can I launch a generic of TYVASO before it's drug patent expiration?
More Information on Dosage
TYVASO family patents
221. Tyvaso Dpi patent expiration
TYVASO DPI IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9604901 | UNITED THERAP | Process to prepare treprostinil, the active ingredient in Remodulin® |
Dec, 2028
(4 years from now) | |
| US11723887 | UNITED THERAP | Process to prepare treprostinil, the active ingredient in Remodulin® |
Dec, 2028
(4 years from now) | |
| US9593066 | UNITED THERAP | Process to prepare treprostinil, the active ingredient in remodulin® |
Dec, 2028
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 23, 2025 |
Drugs and Companies using TREPROSTINIL ingredient
Market Authorisation Date: 23 May, 2022
Treatment: NA
Dosage: POWDER
More Information on Dosage
TYVASO DPI family patents
222. Utibron patent expiration
UTIBRON's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8479730 | NOVARTIS | Inhaler device |
Oct, 2028
(3 years from now) | |
| US8182838 | NOVARTIS | Dry powder composition comprising co-jet milled particles for pulmonary inhalation |
Oct, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 01, 2016 |
| New Product(NP) | Oct 29, 2018 |
Drugs and Companies using GLYCOPYRROLATE; INDACATEROL MALEATE ingredient
NCE-1 date: 02 July, 2015
Market Authorisation Date: 29 October, 2015
Treatment: NA
Dosage: POWDER
More Information on Dosage
UTIBRON family patents
223. Vafseo patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7811595 | AKEBIA | Prolyl hydroxylase inhibitors and methods of use |
Mar, 2028
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8323671 | AKEBIA | Prolyl hydroxylase inhibitors and methods of use |
Apr, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 27, 2029 |
Drugs and Companies using VADADUSTAT ingredient
NCE-1 date: 27 March, 2028
Market Authorisation Date: 27 March, 2024
Treatment: Treatment of anemia due to chronic kidney disease in adults who have been receiving dialysis for at least three months
Dosage: TABLET
More Information on Dosage
VAFSEO family patents
224. Vanflyta patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7820657 | DAIICHI SANKYO INC | Imidazolothiazole compounds for the treatment of disease |
Sep, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 20, 2028 |
| Orphan Drug Exclusivity(ODE-437) | Jul 20, 2030 |
Drugs and Companies using QUIZARTINIB DIHYDROCHLORIDE ingredient
NCE-1 date: 21 July, 2027
Market Authorisation Date: 20 July, 2023
Treatment: NA
Dosage: TABLET
More Information on Dosage
VANFLYTA family patents
225. Varubi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7049320 | TERSERA | NK1 antagonists |
Aug, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 01, 2020 |
Drugs and Companies using ROLAPITANT HYDROCHLORIDE ingredient
NCE-1 date: 02 September, 2019
Market Authorisation Date: 01 September, 2015
Treatment: Prevention of delayed nausea and vomiting associated with emetogenic cancer chemotherapy
Dosage: TABLET; EMULSION
More Information on Dosage
VARUBI family patents
226. Velphoro patent expiration
VELPHORO's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10695367 | VIFOR FRESENIUS | Pharmaceutical compositions |
Nov, 2028
(4 years from now) | |
| US10933090 | VIFOR FRESENIUS | Pharmaceutical compositions |
Nov, 2028
(4 years from now) | |
| US10682376 | VIFOR FRESENIUS | Pharmaceutical compositions |
Nov, 2028
(4 years from now) | |
| US11013761 | VIFOR FRESENIUS | Pharmaceutical compositions |
Nov, 2028
(4 years from now) | |
| US10925897 | VIFOR FRESENIUS | Pharmaceutical compositions |
Nov, 2028
(4 years from now) | |
| US11013762 | VIFOR FRESENIUS | Pharmaceutical compositions |
Nov, 2028
(4 years from now) | |
| US10925896 | VIFOR FRESENIUS | Pharmaceutical compositions |
Nov, 2028
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Nov 27, 2016 |
| New Patient Population(NPP) | Jul 01, 2027 |
| Pediatric Exclusivity(PED) | Jan 01, 2028 |
Drugs and Companies using FERRIC OXYHYDROXIDE ingredient
Market Authorisation Date: 27 November, 2013
Treatment: NA
Dosage: TABLET, CHEWABLE
More Information on Dosage
VELPHORO family patents
227. Veltassa patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8147873 | VIFOR PHARMA | Methods and compositions for treatment of ion imbalances |
Jun, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 21, 2020 |
| New Patient Population(NPP) | Oct 02, 2026 |
| New Strength(NS) | Oct 02, 2026 |
Drugs and Companies using PATIROMER SORBITEX CALCIUM ingredient
NCE-1 date: 22 October, 2019
Market Authorisation Date: 02 October, 2023
Treatment: NA
Dosage: POWDER
How can I launch a generic of VELTASSA before it's drug patent expiration?
More Information on Dosage
VELTASSA family patents
228. Venlafaxine Besylate patent expiration
VENLAFAXINE BESYLATE IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7776358 | ALMATICA | Extended release venlafaxine besylate tablets |
May, 2028
(3 years from now) | |
Drugs and Companies using VENLAFAXINE BESYLATE ingredient
Market Authorisation Date: 29 June, 2022
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE
More Information on Dosage
VENLAFAXINE BESYLATE family patents
229. Versacloz patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8057811 | TASMAN PHARMA | Stable clozapine suspension formulation |
May, 2028
(3 years from now) | |
Drugs and Companies using CLOZAPINE ingredient
Market Authorisation Date: 06 February, 2013
Treatment: NA
Dosage: SUSPENSION
More Information on Dosage
VERSACLOZ family patents
230. Viberzi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8691860 | ABBVIE | Crystals and process of making 5-({(2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(-4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid |
Jul, 2028
(3 years from now) | |
| US9115091 | ABBVIE | Crystals and process of making 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl—1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid |
Jul, 2028
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9789125 | ABBVIE | Crystals and process of making 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid |
Jul, 2028
(3 years from now) | |
| US9364489 | ABBVIE | Crystals and process of making 5-({[2-amino-3-(4-Carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid |
Jul, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 27, 2020 |
Drugs and Companies using ELUXADOLINE ingredient
NCE-1 date: 28 May, 2019
Market Authorisation Date: 27 May, 2015
Treatment: Treatment of pain associated with irritable bowel syndrome with diarrhea (ibs-d) with viberzi (eluxadoline); Treatment of irritable bowel syndrome with diarrhea (ibs-d) with viberzi (eluxadoline).; Tr...
Dosage: TABLET
How can I launch a generic of VIBERZI before it's drug patent expiration?
More Information on Dosage
VIBERZI family patents
231. Viekira Pak (copackaged) patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8501238 | ABBVIE | Anti-infective agents and uses thereof |
Dec, 2028
(4 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9139536 | ABBVIE | Anti-infective agents and uses thereof |
Nov, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosing Schedule(D-163) | Apr 22, 2019 |
| New Chemical Entity Exclusivity(NCE) | Dec 19, 2019 |
Drugs and Companies using DASABUVIR SODIUM; OMBITASVIR, PARITAPREVIR, RITONAVIR ingredient
NCE-1 date: 19 December, 2018
Market Authorisation Date: 19 December, 2014
Treatment: Treatment of hcv infection using dasabuvir; Use of dasabuvir to inhibit viral replication for the treatment of hcv infection.
Dosage: TABLET
More Information on Dosage
VIEKIRA PAK (COPACKAGED) family patents
232. Viekira Xr patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8501238 | ABBVIE | Anti-infective agents and uses thereof |
Sep, 2028
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9139536 | ABBVIE | Anti-infective agents and uses thereof |
Nov, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 19, 2019 |
Drugs and Companies using DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR ingredient
NCE-1 date: 19 December, 2018
Market Authorisation Date: 22 July, 2016
Treatment: Treatment of hcv infection using dasabuvir; Use of dasabuvir to inhibit viral replication for the treatment of hcv infection.
Dosage: TABLET, EXTENDED RELEASE
More Information on Dosage
VIEKIRA XR family patents
233. Vizamyl patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8916131 | GE HEALTHCARE | Radiopharmaceutical composition |
Sep, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 25, 2018 |
Drugs and Companies using FLUTEMETAMOL F-18 ingredient
NCE-1 date: 25 October, 2017
Market Authorisation Date: 25 October, 2013
Treatment: NA
Dosage: INJECTABLE
More Information on Dosage
VIZAMYL family patents
234. Vizimpro patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7772243 | PFIZER | 4-phenylamino-quinazolin-6-yl-amides |
Aug, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 27, 2023 |
| Orphan Drug Exclusivity(ODE-206) | Sep 27, 2025 |
| Orphan Drug Exclusivity(ODE-213) | Sep 27, 2025 |
Drugs and Companies using DACOMITINIB ingredient
NCE-1 date: 27 September, 2022
Market Authorisation Date: 27 September, 2018
Treatment: NA
Dosage: TABLET
More Information on Dosage
VIZIMPRO family patents
235. Vonjo patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9573964 | CTI BIOPHARMA CORP | Oxygen linked pyrimidine derivatives |
May, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 28, 2027 |
| Orphan Drug Exclusivity(ODE-397) | Feb 28, 2029 |
Drugs and Companies using PACRITINIB CITRATE ingredient
NCE-1 date: 28 February, 2026
Market Authorisation Date: 28 February, 2022
Treatment: Treatment of myelofibrosis with pacritinib
Dosage: CAPSULE
More Information on Dosage
VONJO family patents
236. Voquezna patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7977488 | PHATHOM | 1-heterocyclylsulfonyl, 2-aminomethyl, 5-(hetero-) aryl substituted 1-H-pyrrole derivatives as acid secretion inhibitors |
Aug, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Nov 01, 2026 |
| New Chemical Entity Exclusivity(NCE) | May 03, 2027 |
| New Indication(I-948) | Jul 17, 2027 |
Drugs and Companies using VONOPRAZAN FUMARATE ingredient
NCE-1 date: 03 May, 2026
Market Authorisation Date: 01 November, 2023
Treatment: NA
Dosage: TABLET
More Information on Dosage
VOQUEZNA family patents
237. Voquezna Dual Pak patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7977488 | PHATHOM | 1-heterocyclylsulfonyl, 2-aminomethyl, 5-(hetero-) aryl substituted 1-H-pyrrole derivatives as acid secretion inhibitors |
Aug, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 03, 2027 |
| Generating Antibiotic Incentives Now(GAIN) | May 03, 2032 |
Drugs and Companies using AMOXICILLIN; VONOPRAZAN FUMARATE ingredient
NCE-1 date: 04 May, 2031
Market Authorisation Date: 03 May, 2022
Treatment: NA
Dosage: CAPSULE, TABLET
More Information on Dosage
VOQUEZNA DUAL PAK family patents
238. Voquezna Triple Pak patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7977488 | PHATHOM | 1-heterocyclylsulfonyl, 2-aminomethyl, 5-(hetero-) aryl substituted 1-H-pyrrole derivatives as acid secretion inhibitors |
Aug, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 03, 2027 |
| Generating Antibiotic Incentives Now(GAIN) | May 03, 2032 |
Drugs and Companies using AMOXICILLIN; CLARITHROMYCIN; VONOPRAZAN FUMARATE ingredient
NCE-1 date: 04 May, 2031
Market Authorisation Date: 03 May, 2022
Treatment: NA
Dosage: CAPSULE, TABLET, TABLET
More Information on Dosage
VOQUEZNA TRIPLE PAK family patents
239. Vosevi patent expiration
VOSEVI's oppositions filed in EPO
VOSEVI IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9085573 | GILEAD SCIENCES INC | NA |
Mar, 2028
(3 years from now) | |
| US8580765 | GILEAD SCIENCES INC | NA |
Mar, 2028
(3 years from now) | |
| US9585906 | GILEAD SCIENCES INC | NA |
Mar, 2028
(3 years from now) | |
| US8735372 | GILEAD SCIENCES INC | NA |
Mar, 2028
(3 years from now) | |
| US8334270 | GILEAD SCIENCES INC | NA |
Mar, 2028
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8957046 | GILEAD SCIENCES INC | NA |
Mar, 2028
(3 years from now) | |
|
US9085573 (Pediatric) | GILEAD SCIENCES INC | NA |
Sep, 2028
(3 years from now) | |
|
US8735372 (Pediatric) | GILEAD SCIENCES INC | NA |
Sep, 2028
(3 years from now) | |
|
US8580765 (Pediatric) | GILEAD SCIENCES INC | NA |
Sep, 2028
(3 years from now) | |
|
US8334270 (Pediatric) | GILEAD SCIENCES INC | NA |
Sep, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 18, 2022 |
Drugs and Companies using SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR ingredient
NCE-1 date: 18 July, 2021
Market Authorisation Date: 18 July, 2017
Treatment: Treatment of adult patients with chronic hcv infection who have genotype 1, 2, 3, 4, 5, or 6 infection and have previously been treated with an hcv regimen containing an ns5a inhibitor; Treatment of a...
Dosage: TABLET
More Information on Dosage
VOSEVI family patents
240. Vraylar patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7943621 | ABBVIE | Salts of piperazine compounds as D3/D2 antagonists |
Dec, 2028
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 17, 2020 |
| M(M-213) | Nov 09, 2020 |
| New Indication(I-798) | May 24, 2022 |
| New Indication(I-904) | Dec 16, 2025 |
Drugs and Companies using CARIPRAZINE HYDROCHLORIDE ingredient
NCE-1 date: 18 September, 2019
Market Authorisation Date: 17 September, 2015
Treatment: NA
Dosage: CAPSULE
How can I launch a generic of VRAYLAR before it's drug patent expiration?
More Information on Dosage
VRAYLAR family patents
241. Vusion patent expiration
VUSION IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8147852 | MYLAN | Modified azole compounds as antifungal and antibacterial agents |
Mar, 2028
(3 years from now) | |
Drugs and Companies using MICONAZOLE NITRATE; WHITE PETROLATUM; ZINC OXIDE ingredient
Market Authorisation Date: 16 February, 2006
Treatment: Use for treatment of diaper dermatitis complicated by candidiasis
Dosage: OINTMENT
More Information on Dosage
VUSION family patents
242. Vyondys 53 patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| USRE47691 | SAREPTA THERAPS INC | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
Jun, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 12, 2024 |
| Orphan Drug Exclusivity(ODE-280) | Dec 12, 2026 |
Drugs and Companies using GOLODIRSEN ingredient
NCE-1 date: 13 December, 2023
Market Authorisation Date: 12 December, 2019
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
VYONDYS 53 family patents
243. Winlevi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9486458 | SUN PHARM | Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives |
Jul, 2028
(3 years from now) | |
| US11938141 | SUN PHARM | Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives |
Jul, 2028
(3 years from now) | |
| US10159682 | SUN PHARM | Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives |
Aug, 2028
(3 years from now) | |
| US11207332 | SUN PHARM | Enzymatic process for obtaining 17 α-monoesters of cortexolone and/or its 9,11-dehydroderivatives |
Nov, 2028
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 26, 2025 |
Drugs and Companies using CLASCOTERONE ingredient
NCE-1 date: 26 August, 2024
Market Authorisation Date: 26 August, 2020
Treatment: Method of treating acne vulgaris with topically applied cortexolone 17a-propionate; Method of treating acne vulgaris with topically applied cortexolone 17alpha-propionate
Dosage: CREAM
More Information on Dosage
WINLEVI family patents
244. Xadago patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8076515 | MDD US | Process for the production of 2-[4-(3- and 2-fluorobenzyloxy) benzylamino] propanamides |
Dec, 2028
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 21, 2022 |
Drugs and Companies using SAFINAMIDE MESYLATE ingredient
NCE-1 date: 21 March, 2021
Market Authorisation Date: 21 March, 2017
Treatment: Adjunctive treatment to levodopa/carbidopa in patients with parkinson's disease experiencing 'off' episodes
Dosage: TABLET
More Information on Dosage
XADAGO family patents
245. Xelpros patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9539262 | SUN PHARM | Ophthalmic composition comprising a prostaglandin |
Oct, 2028
(3 years from now) | |
Drugs and Companies using LATANOPROST ingredient
Market Authorisation Date: 12 September, 2018
Treatment: Reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension
Dosage: EMULSION
More Information on Dosage
XELPROS family patents
246. Xenleta patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8153689 | NABRIVA | Pleuromutilin derivatives for the treatment of diseases mediated by microbes |
Mar, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 19, 2024 |
| Generating Antibiotic Incentives Now(GAIN) | Aug 19, 2029 |
Drugs and Companies using LEFAMULIN ACETATE ingredient
NCE-1 date: 19 August, 2028
Market Authorisation Date: 19 August, 2019
Treatment: NA
Dosage: SOLUTION; TABLET
More Information on Dosage
XENLETA family patents
247. Xermelo patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8653094 | TERSERA | Solid forms of (S)-ethyl 2-amino-3-(4-(2-amino-6-((R)-1-(4-chloro-2-(3-methyl-1H-pyrazol-1-yl)phenyl)-2,2,2-trifluoroethoxy)-pyrimidin-4-yl)phenyl)propanoate and methods of their use |
Dec, 2028
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 28, 2022 |
| Orphan Drug Exclusivity(ODE) | Feb 28, 2024 |
| Orphan Drug Exclusivity(ODE-132) | Feb 28, 2024 |
Drugs and Companies using TELOTRISTAT ETIPRATE ingredient
NCE-1 date: 28 February, 2021
Market Authorisation Date: 28 February, 2017
Treatment: The treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (ssa) therapy in adults inadequately controlled by ssa therapy
Dosage: TABLET
More Information on Dosage
XERMELO family patents
248. Xhance patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11602603 | OPTINOSE US INC | Nasal delivery devices |
Oct, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Sep 18, 2020 |
| New Indication(I-940) | Mar 15, 2027 |
Drugs and Companies using FLUTICASONE PROPIONATE ingredient
Market Authorisation Date: 18 September, 2017
Treatment: Method of delivering fluticasone propionate to a nasal airway
Dosage: SPRAY, METERED
More Information on Dosage
XHANCE family patents
249. Xultophy 100/3.6 patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US9457154 (Pediatric) | NOVO | Injection device with an end of dose feedback mechanism |
Mar, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Nov 21, 2019 |
| New Chemical Entity Exclusivity(NCE) | Sep 25, 2020 |
| M(M-242) | Aug 08, 2022 |
Drugs and Companies using INSULIN DEGLUDEC; LIRAGLUTIDE ingredient
NCE-1 date: 26 September, 2019
Market Authorisation Date: 21 November, 2016
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
XULTOPHY 100/3.6 family patents
250. Yondelis patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8895557 | JANSSEN PRODS | Pharmaceutical formulations of ecteinascidin compounds |
Jan, 2028
(3 years from now) | |
|
US8895557 (Pediatric) | JANSSEN PRODS | Pharmaceutical formulations of ecteinascidin compounds |
Jul, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 23, 2020 |
| M(M-232) | Jun 29, 2021 |
| Orphan Drug Exclusivity(ODE) | Oct 23, 2022 |
| Orphan Drug Exclusivity(ODE-100) | Oct 23, 2022 |
| Pediatric Exclusivity(PED) | Apr 23, 2023 |
Drugs and Companies using TRABECTEDIN ingredient
NCE-1 date: 23 April, 2022
Market Authorisation Date: 23 October, 2015
Treatment: NA
Dosage: POWDER
How can I launch a generic of YONDELIS before it's drug patent expiration?
More Information on Dosage
YONDELIS family patents
251. Yupelri patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7288657 | MYLAN IRELAND LTD | Biphenyl compounds useful as muscarinic receptor antagonists |
Oct, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 09, 2023 |
Drugs and Companies using REVEFENACIN ingredient
NCE-1 date: 09 November, 2022
Market Authorisation Date: 09 November, 2018
Treatment: NA
Dosage: SOLUTION
How can I launch a generic of YUPELRI before it's drug patent expiration?
More Information on Dosage
YUPELRI family patents
252. Yutiq patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7998108 | ALIMERA SCIENCES INC | Injector apparatus and method of use |
Jan, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Nov 12, 2021 |
Drugs and Companies using FLUOCINOLONE ACETONIDE ingredient
Market Authorisation Date: 12 October, 2018
Treatment: A method of injecting an implant
Dosage: IMPLANT
More Information on Dosage
YUTIQ family patents
253. Zemdri patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9688711 | CIPLA USA | Antibacterial aminoglycoside analogs |
Nov, 2028
(4 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9266919 | CIPLA USA | Antibacterial aminoglycoside analogs |
Nov, 2028
(4 years from now) | |
| US8822424 | CIPLA USA | Antibacterial aminoglycoside analogs |
Nov, 2028
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 25, 2023 |
| Generating Antibiotic Incentives Now(GAIN) | Jun 25, 2028 |
Drugs and Companies using PLAZOMICIN SULFATE ingredient
NCE-1 date: 26 June, 2027
Market Authorisation Date: 25 June, 2018
Treatment: Method of using plazomicin to treat bacterial infections
Dosage: SOLUTION
More Information on Dosage
ZEMDRI family patents
254. Zenpep patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8562979 | APTALIS PHARMA US | Stable digestive enzyme compositions |
Feb, 2028
(3 years from now) | |
| US8246950 | APTALIS PHARMA US | Stable digestive enzyme compositions |
Feb, 2028
(3 years from now) | |
| US8221747 | APTALIS PHARMA US | Stable pancreatic enzyme compositions |
Feb, 2028
(3 years from now) | |
| US8562978 | APTALIS PHARMA US | Stable digestive enzyme compositions |
Feb, 2028
(3 years from now) | |
| US7658918 | APTALIS PHARMA US | Stable digestive enzyme compositions |
Feb, 2028
(3 years from now) | |
| US8562980 | APTALIS PHARMA US | Stable digestive enzyme compositions |
Feb, 2028
(3 years from now) | |
| US8562981 | APTALIS PHARMA US | Stable digestive enzyme compositions |
Feb, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 27, 2014 |
Drugs and Companies using PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) ingredient
NCE-1 date: 27 August, 2013
Market Authorisation Date: 25 March, 2014
Treatment: Treatment of exocrine pancreatic insufficiency due to cystic fibrosis or other conditions
Dosage: CAPSULE, DELAYED RELEASE
More Information on Dosage
ZENPEP family patents
255. Zenpep patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8562978 | ZENPEP | Stable digestive enzyme compositions |
Feb, 2028
(3 years from now) | |
| US8562980 | ZENPEP | Stable digestive enzyme compositions |
Feb, 2028
(3 years from now) | |
| US8562981 | ZENPEP | Stable digestive enzyme compositions |
Feb, 2028
(3 years from now) | |
| US8221747 | ZENPEP | Stable pancreatic enzyme compositions |
Feb, 2028
(3 years from now) | |
| US8562979 | ZENPEP | Stable digestive enzyme compositions |
Feb, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 27, 2014 |
Drugs and Companies using PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) ingredient
NCE-1 date: 27 August, 2013
Market Authorisation Date: 25 March, 2014
Treatment: Treatment of exocrine pancreatic insufficiency due to cystic fibrosis or other conditions
Dosage: CAPSULE, DELAYED RELEASE
More Information on Dosage
ZENPEP family patents
256. Zerbaxa patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7129232 | CUBIST PHARMS LLC | Cephem compounds |
May, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 19, 2019 |
| Generating Antibiotic Incentives Now(GAIN) | Dec 19, 2024 |
| New Patient Population(NPP) | Apr 21, 2025 |
Drugs and Companies using CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM ingredient
NCE-1 date: 20 December, 2023
Market Authorisation Date: 19 December, 2014
Treatment: Complicated intra-abdominal infections (ciai), used in combination with metronidazole, in adult and pediatric patients (birth to less than 18 years of age)
Dosage: POWDER
More Information on Dosage
ZERBAXA family patents
257. Zetonna patent expiration
ZETONNA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8371292 | COVIS | Use of ciclesonide for the treatment of respiratory diseases |
Feb, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jan 20, 2015 |
Drugs and Companies using CICLESONIDE ingredient
Market Authorisation Date: 20 January, 2012
Treatment: Treatment of symptoms associated with seasonal and perennial allergic rhinitis in adults and adolescents 12 years of age and older. patent claims methods for treating a respiratory disease in a child
Dosage: AEROSOL, METERED
More Information on Dosage
ZETONNA family patents
258. Zolinza patent expiration
Can you believe ZOLINZA received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8450372 | MSD SUB MERCK | Formulations of suberoylanilide hydroxamic acid and methods for producing same |
Mar, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 06, 2011 |
| Orphan Drug Exclusivity(ODE) | Oct 06, 2013 |
Drugs and Companies using VORINOSTAT ingredient
NCE-1 date: 06 October, 2010
Market Authorisation Date: 06 October, 2006
Treatment: Treatment of cutaneous manifestations in patients with cutaneous t-cell lymphoma (ctcl)
Dosage: CAPSULE
More Information on Dosage
ZOLINZA family patents
259. Zometa patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7932241 | NOVARTIS | Pharmaceutical products comprising bisphosphonates |
Feb, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Pediatric Exclusivity(PED) | Sep 20, 2011 |
Drugs and Companies using ZOLEDRONIC ACID ingredient
Market Authorisation Date: 20 August, 2001
Treatment: NA
Dosage: INJECTABLE
How can I launch a generic of ZOMETA before it's drug patent expiration?
More Information on Dosage
ZOMETA family patents
260. Zuragard patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8703828 | ZUREX PHARMA | Antimicrobial compositions and methods of use |
May, 2028
(3 years from now) | |
| US9629368 | ZUREX PHARMA | Antimicrobial compositions and methods of use |
May, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Apr 26, 2022 |
| M(M-268) | Jun 24, 2024 |
Drugs and Companies using ISOPROPYL ALCOHOL ingredient
Market Authorisation Date: 26 April, 2019
Treatment: Use as an antiseptic for the preparation of a patient's skin prior to surgery
Dosage: SOLUTION
More Information on Dosage
ZURAGARD family patents
261. Zurampic patent expiration
Can you believe ZURAMPIC received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10183012 | IRONWOOD PHARMS INC | Compounds and compositions and methods of use |
Nov, 2028
(4 years from now) | |
| US8283369 | IRONWOOD PHARMS INC | Compounds and compositions and methods of use |
Nov, 2028
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 22, 2020 |
Drugs and Companies using LESINURAD ingredient
NCE-1 date: 23 December, 2019
Market Authorisation Date: 22 December, 2015
Treatment: Treatment of hyperuricemia associated with gout in patients who have not achieved target serum uric acid levels with a xanthine oxidase inhibitor alone; Treatment of gout
Dosage: TABLET
More Information on Dosage
ZURAMPIC family patents
262. Zykadia patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7964592 | NOVARTIS | 2,4-di (phenylamino) pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders |
Apr, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 29, 2019 |
| M(M-199) | May 26, 2020 |
| Orphan Drug Exclusivity(ODE-66) | Apr 29, 2021 |
| Orphan Drug Exclusivity(ODE) | May 26, 2024 |
| ODE*(ODE*) | May 26, 2024 |
| Orphan Drug Exclusivity(ODE-145) | May 26, 2024 |
Drugs and Companies using CERITINIB ingredient
NCE-1 date: 29 April, 2018
Market Authorisation Date: 29 April, 2014
Treatment: NA
Dosage: TABLET
More Information on Dosage
ZYKADIA family patents
List of large molecules
1. List of Actemra large molecules
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| US8398980 | GENENTECH, INC. | Subtypes of humanized antibody against interleukin-6 receptor |
Feb, 2028
(3 years from now) | |
| US11078294 | GENENTECH, INC. | Prevention of disulfide bond reduction during recombinant production of polypeptides |
Jul, 2028
(3 years from now) | |
| US8574869 | GENENTECH, INC. | Prevention of disulfide bond reduction during recombinant production of polypeptides |
Jul, 2028
(3 years from now) | |
| US11008394 | GENENTECH, INC. | High concentration antibody-containing liquid formulation |
Dec, 2028
(4 years from now) | |
| US11359026 | GENENTECH, INC. | High concentration antibody-containing liquid formulation |
Dec, 2028
(4 years from now) | |
| US11584798 | GENENTECH, INC. | High concentration antibody-containing liquid formulation |
Dec, 2028
(4 years from now) |
Ingredients: TOCILIZUMAB
2. List of Eylea large molecules
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| US9562238 | REGENERON PHARMACEUTICALS, INC. | Enhanced expression and stability regions |
Jun, 2028
(3 years from now) | |
| US9932605 | REGENERON PHARMACEUTICALS, INC. | Enhanced expression and stability regions |
Jun, 2028
(3 years from now) | |
| US9222106 | REGENERON PHARMACEUTICALS, INC. | Enhanced expression and stability regions |
Jun, 2028
(3 years from now) | |
| US10415055 | REGENERON PHARMACEUTICALS, INC. | Enhanced expression and stability regions |
Jun, 2028
(3 years from now) | |
| US7771997 | REGENERON PHARMACEUTICALS, INC. | Enhanced expression and stability regions |
Jul, 2028
(3 years from now) |
Ingredients: AFLIBERCEPT
3. List of Humira large molecules
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| US9669093 | ABBVIE INC. | Methods for treating juvenile idiopathic arthritis |
Jun, 2028
(3 years from now) | |
| US9284370 | ABBVIE INC. | Methods for treating juvenile idiopathic arthritis |
Jun, 2028
(3 years from now) | |
| US9085619 | ABBVIE INC. | Anti-TNF antibody formulations |
Nov, 2028
(4 years from now) | |
| US11167030 | ABBVIE INC. | Protein formulations and methods of making same |
Nov, 2028
(4 years from now) | |
| US11191834 | ABBVIE INC. | Protein formulations and methods of making same |
Nov, 2028
(4 years from now) |
Ingredients: ADALIMUMAB
4. List of Avastin large molecules
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| US10906986 | GENENTECH, INC. | Prevention of disulfide bond reduction during recombinant production of polypeptides |
Jul, 2028
(3 years from now) |
Ingredients: BEVACIZUMAB
5. List of Rituxan large molecules
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| US10759866 | GENENTECH, INC. | Prevention of disulfide bond reduction during recombinant production of polypeptides |
Jul, 2028
(3 years from now) |
Ingredients: RITUXIMAB
6. List of Herceptin large molecules
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| US10808037 | GENENTECH, INC. | Prevention of disulfide bond reduction during recombinant production of polypeptides |
Jul, 2028
(3 years from now) |
Ingredients: TRASTUZUMAB
7. List of Xolair large molecules
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| US11987637 | GENENTECH, INC. | Prevention of disulfide bond reduction during recombinant production of polypeptides |
Jul, 2028
(3 years from now) |
Ingredients: OMALIZUMAB